S-6/A 1 s6a.htm AMENDMENT TO REGISTRATION STATEMENT

Registration No. 333-267939

1940 Act No. 811-05903

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Amendment No. 1 to Form S-6

FOR REGISTRATION UNDER THE SECURITIES ACT OF 1933 OF SECURITIES OF UNIT INVESTMENT TRUSTS REGISTERED ON FORM N-8B-2

A.Exact name of trust:

FT 10412

B.Name of depositor:

FIRST TRUST PORTFOLIOS L.P.

C.Complete address of depositor's principal executive offices:

120 East Liberty Drive

Suite 400

Wheaton, Illinois 60187

D.Name and complete address of agents for service:

	Copy to:

JAMES A. BOWEN	ERIC F. FESS
c/o First Trust Portfolios L.P.	c/o Chapman and Cutler LLP
120 East Liberty Drive	320 South Canal Street
Suite 400	27th Floor
Wheaton, Illinois 60187	Chicago, Illinois 60606

E.Title and Amount of Securities Being Registered:

An indefinite number of Units pursuant to Rule 24f-2 promulgated under the Investment Company Act of 1940, as amended.

F.Approximate date of proposed sale to public:

As soon as practicable after the effective date of the Registration Statement.

| |Check box if it is proposed that this filing will become effective on December 1, 2022 at 2:00 p.m. pursuant to Rule 487.

The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

________________________________

Defensive Equity Buy-Write Portfolio Series

FT 10412

FT 10412 is a series of a unit investment trust, the FT Series. FT 10412
consists of a single portfolio known as Defensive Equity Buy-Write Portfolio
Series (the "Trust"). The Trust invests in a portfolio of common stocks
("Common Stocks") and U.S. Treasury securities ("Treasury Obligations"). The
Common Stocks will be subject to exchange-traded Long Term Equity AnticiPation
Securities ("LEAPS(R)" or "Covered Call Options") which give the option holder
the right to buy the Common Stocks from the Trust at a predetermined price on
any business day prior to the LEAPS'(R) expiration date (January 19, 2024),
which means the Trust gives up any increase in the Common Stock above that
price. Collectively, the Common Stocks, Treasury Obligations and LEAPS(R) are
referred to as the "Securities." The Trust seeks income, with limited capital
appreciation as a secondary objective.

THE SECURITIES AND EXCHANGE COMMISSION ("SEC") HAS NOT APPROVED OR DISAPPROVED
OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OF THIS PROSPECTUS. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

FIRST TRUST(R)

800-621-1675

The date of this prospectus is December 1, 2022

Page 1

Table of Contents

Summary of Essential Information 3
Fee Table 4
Report of Independent Registered Public Accounting Firm 5
Statement of Net Assets 6
Schedule of Investments 7
The FT Series 10
Portfolio 11
Risk Factors 12
Public Offering 17
Distribution of Units 20
The Sponsor's Profits 21
The Secondary Market 21
How We Purchase Units 21
Expenses and Charges 22
Tax Status 22
Retirement Plans 24
Rights of Unit Holders 24
Income and Capital Distributions 25
Redeeming Your Units 25
Removing Securities from the Trust 26
Amending or Terminating the Indenture 27
Information on the Sponsor and Trustee 28
Other Information 29

Page 2

Summary of Essential Information (Unaudited)

Defensive Equity Buy-Write Portfolio Series
FT 10412

At the Opening of Business on the Initial Date of Deposit-December 1, 2022

Sponsor: First Trust Portfolios L.P.
Trustee: The Bank of New York Mellon

Initial Number of Units (1) 183,202
Fractional Undivided Interest in the Trust per Unit (1) 1/183,202
Public Offering Price:
Public Offering Price per Unit (2) $ 10.000
Less Initial Sales Charge per Unit (3) (.000)
__________
Aggregate Offering Price Evaluation of Securities per Unit (4) 10.000
Less Deferred Sales Charge per Unit (3) (.135)
__________
Redemption Price per Unit (5) 9.865
Less Creation and Development Fee per Unit (3) (5) (.050)
Less Organization Costs per Unit (5) (.039)
__________
Net Asset Value per Unit $ 9.776
==========
Cash CUSIP Number 30329L 542
Fee Account Cash CUSIP Number 30329L 559
Pricing Line Product Code 144655
Ticker Symbol FPHVSX

First Settlement Date December 5, 2022
Mandatory Termination Date (6) January 24, 2024
Income Distribution Record Date Tenth day of each June and December, commencing June 10, 2023.
Income Distribution Date (7) Twenty-fifth day of each June and December, commencing June 25, 2023.

_____________

(1) As of the Evaluation Time on the Initial Date of Deposit, we may adjust
the number of Units of the Trust so that the Public Offering Price per Unit
will equal approximately $10.00. If we make such an adjustment, the fractional
undivided interest per Unit will vary from the amount indicated above.

(2) The Public Offering Price shown above reflects the value of the Securities
on the business day prior to the Initial Date of Deposit. No investor will
purchase Units at this price. The price you pay for your Units will be based
on their valuation at the Evaluation Time on the date you purchase your Units.
On the Initial Date of Deposit, the Public Offering Price per Unit will not
include any accumulated dividends on the Common Stocks or accrued interest on
the Treasury Obligations. After this date, a pro rata share of any accumulated
dividends on the Common Stocks and accrued interest on the Treasury
Obligations will be included. In calculating the price of a Unit, the value of
the Common Stocks is reduced by the value of the LEAPS(R).

(3) You will pay a maximum sales charge of 1.85% of the Public Offering Price
per Unit (equivalent to 1.85% of the net amount invested) which consists of an
initial sales charge, a deferred sales charge and a creation and development
fee. The sales charges are described in the "Fee Table."

(4) Each listed Common Stock is valued at its last closing sale price at the
Evaluation Time on the business day prior to the Initial Date of Deposit. Each
Treasury Obligation is valued at its last offering price. If a Common Stock is
not listed, or if no closing sale price exists, it is valued at its closing
ask price on such date. LEAPS(R) are valued at their last closing sale price,
or if no closing sale price exists, at their closing bid price. The value of
the LEAPS(R) is then netted against the value of the Common Stocks. See
"Public Offering-The Value of the Securities." Evaluations for purposes of
determining the purchase, sale or redemption price of Units are made as of the
close of trading on the New York Stock Exchange ("NYSE") (generally 4:00 p.m.
Eastern time) on each day on which it is open (the "Evaluation Time").

(5) The creation and development fee and the estimated organization costs per
Unit will be deducted from the assets of the Trust at the end of the initial
offering period. If Units are redeemed prior to any such reduction, these fees
will not be deducted from the redemption proceeds. See "Redeeming Your Units."

(6) See "Amending or Terminating the Indenture."

(7) The Trustee will distribute money from the Income Account, as determined
at the semi-annual Record Date, semi-annually on the twenty-fifth day of each
June and December to Unit holders of record on the tenth day of such months
provided the amount in the Income Account equals at least $1.00 per 100 Units.
The Trustee will make distributions from the Capital Account monthly on the
twenty-fifth day of each month to Unit holders of record on the tenth day of
such month provided the amount available for distribution from the Capital
Account equals at least $1.00 per 100 Units. See "Income and Capital
Distributions."

Page 3

Fee Table (Unaudited)

This Fee Table describes the fees and expenses that you may, directly or
indirectly, pay if you buy and hold Units of the Trust. See "Public Offering"
and "Expenses and Charges." Although the Trust has a term of approximately 14
months and is a unit investment trust rather than a mutual fund, this
information allows you to compare fees.

Amount
per Unit
________
Unit Holder Sales Fees (as a percentage of public offering price)

Maximum Sales Charge
Initial sales charge 0.00%(a) $.000
Deferred sales charge 1.35%(b) $.135
Creation and development fee 0.50%(c) $.050
_____ _____
Maximum sales charge (including creation and development fee) 1.85% $.185
===== =====
Organization Costs (as a percentage of public offering price)
Estimated organization costs .390%(d) $.0390
===== ======
Estimated Annual Trust Operating Expenses(e)
(as a percentage of average net assets)
Portfolio supervision, bookkeeping, administrative and evaluation fees .079% $.0080
Trustee's fee and other operating expenses .136%(f) $.0138
_____ ______
Total .215% $.0218
===== ======

Example

This example is intended to help you compare the cost of investing in the
Trust with the cost of investing in other investment products. The example
assumes that you invest $10,000 in the Trust for the periods shown. The
example also assumes a 5% return on your investment each year and that the
Trust's operating expenses stay the same. The example does not take into
consideration transaction fees which may be charged by certain broker/dealers
for processing redemption requests. Although your actual costs may vary, based
on these assumptions your costs, assuming you sell or redeem your Units at the
end of each period, would be:

1 Year 14 Months
______ _______
$246 $250

The example will not differ if you hold rather than sell your Units at the end
of each period.

_____________

(a) The combination of the initial and deferred sales charge comprises what we
refer to as the "transactional sales charge." The initial sales charge is
actually equal to the difference between the maximum sales charge of 1.85% and
the sum of any remaining deferred sales charge and creation and development
fee. When the Public Offering Price per Unit equals $10, there is no initial
sales charge. If the price you pay for your Units exceeds $10 per Unit, you
will pay an initial sales charge.

(b) The deferred sales charge is a fixed dollar amount equal to $.135 per Unit
which, as a percentage of the Public Offering Price, will vary over time. The
deferred sales charge will be deducted in three monthly installments
commencing February 17, 2023.

(c) The creation and development fee compensates the Sponsor for creating and
developing the Trust. The creation and development fee is a charge of $.050
per Unit collected at the end of the initial offering period, which is
expected to be within approximately two months after the Initial Date of
Deposit. If the price you pay for your Units exceeds $10 per Unit, the
creation and development fee will be less than 0.50%; if the price you pay for
your Units is less than $10 per Unit, the creation and development fee will
exceed 0.50%. If you purchase Units after the initial offering period, you
will not be assessed the creation and development fee.

(d) Estimated organization costs will be deducted from the assets of the Trust
at the end of the initial offering period. Estimated organization costs are
assessed on a fixed dollar amount per Unit basis which, as a percentage of
average net assets, will vary over time.

(e) Each of the fees listed herein is assessed on a fixed dollar amount per
Unit basis which, as a percentage of average net assets, will vary over time.

(f) Other operating expenses for the Trust do not include brokerage costs and
other portfolio transaction fees for the Trust. In certain circumstances the
Trust may incur additional expenses not set forth above. See "Expenses and
Charges."

Page 4

Report of Independent
Registered Public Accounting Firm

To the Unit Holders and the Sponsor, First Trust Portfolios L.P., of FT 10412

Opinion on the Statement of Net Assets

We have audited the accompanying statement of net assets of FT 10412,
comprising Defensive Equity Buy-Write Portfolio Series (the "Trust"), one of
the series constituting the FT Series, including the schedule of investments,
as of the opening of business on December 1, 2022 (Initial Date of Deposit),
and the related notes. In our opinion, the statement of net assets presents
fairly, in all material respects, the financial position of the Trust as of
the opening of business on December 1, 2022 (Initial Date of Deposit), in
conformity with accounting principles generally accepted in the United States
of America.

Basis for Opinion

This statement of net assets is the responsibility of the Trust's Sponsor. Our
responsibility is to express an opinion on this statement of net assets based
on our audit. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to
be independent with respect to the Trust in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and
Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those
standards require that we plan and perform the audit to obtain reasonable
assurance about whether the statement of net assets is free of material
misstatement, whether due to error or fraud. The Trust is not required to
have, nor were we engaged to perform, an audit of its internal control over
financial reporting. As part of our audit we are required to obtain an
understanding of internal control over financial reporting but not for the
purpose of expressing an opinion on the effectiveness of the Trust's internal
control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material
misstatement of the statement of net assets, whether due to error or fraud,
and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and
disclosures in the statement of net assets. Our audit also included evaluating
the accounting principles used and significant estimates made by the Trust's
Sponsor, as well as evaluating the overall presentation of the statement of
net assets. Our procedures included confirmation of the irrevocable letter of
credit held by The Bank of New York Mellon, the Trustee, and deposited in the
Trust for the purchase of securities, as shown in the statement of net assets,
as of the opening of business on December 1, 2022, by correspondence with the
Trustee. We believe that our audit provides a reasonable basis for our opinion.

/s/ DELOITTE & TOUCHE LLP

Chicago, Illinois
December 1, 2022

We have served as the auditor of one or more investment companies sponsored by
First Trust Portfolios L.P. since 2001.

Page 5

Statement of Net Assets

Defensive Equity Buy-Write Portfolio Series
FT 10412

At the Opening of Business on the Initial Date of Deposit-December 1, 2022

NET ASSETS

Investment in Securities represented by purchase contracts (1) (2) $1,937,881
Accrued interest on underlying Treasury Obligations (2) (3) 650
Less liability for call options written-LEAPS(R) (1) (4) (105,862)
Less distributions payable (3) (650)
Less liability for reimbursement to Sponsor for organization costs (5) (7,145)
Less liability for deferred sales charge (6) (24,732)
Less liability for creation and development fee (7) (9,160)
__________
Net assets $1,790,982
==========

Units outstanding 183,202
Net asset value per Unit (8) $ 9.776

ANALYSIS OF NET ASSETS

Cost to investors (9) $1,832,019
Less maximum sales charge (9) (33,892)
Less estimated reimbursement to Sponsor for organization costs (5) (7,145)
__________
Net assets $1,790,982
==========

______________

NOTES TO STATEMENT OF NET ASSETS

The Trust is registered as a unit investment trust under the Investment
Company Act of 1940. The Sponsor is responsible for the preparation of
financial statements in accordance with accounting principles generally
accepted in the United States which require the Sponsor to make estimates and
assumptions that affect amounts reported herein. Actual results could differ
from those estimates. The Trust intends to comply in its initial fiscal year
and thereafter with provisions of the Internal Revenue Code applicable to
regulated investment companies and as such, will not be subject to federal
income taxes on otherwise taxable income (including net realized capital
gains) distributed to Unit holders.

(1) The Trust invests in a portfolio of Common Stocks and Treasury Obligations
with the Common Stocks subject to LEAPS(R). Aggregate cost of the Securities
listed under "Schedule of Investments" and the liability for the LEAPS(R) are
based on their aggregate underlying value. The Securities and the LEAPS(R)
were deposited at prices equal to their market value as determined by the
Sponsor. The Trust has a Mandatory Termination Date of January 24, 2024.

(2) An irrevocable letter of credit issued by The Bank of New York Mellon, of
which approximately $3,000,000 will be allocated to the Trust, has been
deposited with the Trustee as collateral, covering the monies necessary to
satisfy the amounts set forth below:

Aggregate Offering Price of
Common Stocks and Treasury Obligations Accrued Interest to Initial Date of Deposit Accrued Interest to Expected Date of Delivery
______________________________________ ___________________________________________ _____________________________________________
$1,937,881 $650 $6

(3) The Trustee will advance to the Trust the amount of net interest accrued
to the First Settlement Date which will be distributed to the Sponsor as Unit
holder of record.

(4) The Trust will enter into option contracts which provide the option
purchaser with the right, but not the obligation, to buy a security at a
predetermined exercise price during a defined period. The option purchaser
pays a premium to the option writer for the right to exercise the option. The
option writer is obligated to sell the security underlying the contract at a
set price, if the option purchaser chooses to exercise the option. As a writer
of an option contract, the Trust is not subject to credit risk but is subject
to market risk, since the Trust is obligated to make payments under the terms
of the option contract if exercised. The Trust uses exchange-traded contracts
that have standardized terms and performance mechanics.

(5) A portion of the Public Offering Price consists of an amount sufficient to
reimburse the Sponsor for all or a portion of the costs of establishing the
Trust. These costs have been estimated at $.0390 per Unit. A payment will be
made at the end of the initial offering period to an account maintained by the
Trustee from which the obligation of the investors to the Sponsor will be
satisfied. To the extent that actual organization costs of the Trust are
greater than the estimated amount, only the estimated organization costs added
to the Public Offering Price will be reimbursed to the Sponsor and deducted
from the assets of the Trust.

(6) Represents the amount of mandatory deferred sales charge distributions of
$.135 per Unit, payable to the Sponsor in three equal monthly installments
beginning on February 17, 2023 and on the twentieth day of each month
thereafter (or if such date is not a business day, on the preceding business
day) through April 20, 2023. If Unit holders redeem Units before April 20,
2023, they will have to pay the remaining amount of the deferred sales charge
applicable to such Units when they redeem them.

(7) The creation and development fee ($.050 per Unit) is payable by the Trust
on behalf of Unit holders out of assets of the Trust at the end of the initial
offering period. If Units are redeemed prior to the close of the initial
offering period, the fee will not be deducted from the proceeds.

(8) Net asset value per Unit is calculated by dividing the Trust's net assets
by the number of Units outstanding. This figure includes organization costs
and the creation and development fee, which will only be assessed to Units
outstanding at the end of the initial offering period.

(9) The aggregate cost to investors in the Trust includes a maximum sales
charge (comprised of an initial sales charge, a deferred sales charge and the
creation and development fee) computed at the rate of 1.85% of the Public
Offering Price per Unit (equivalent to 1.85% of the net amount invested,
exclusive of the deferred sales charge and the creation and development fee),
assuming no reduction of the maximum sales charge as set forth under "Public
Offering."

Page 6

Schedule of Investments

Defensive Equity Buy-Write Portfolio Series
FT 10412

At the Opening of Business on the Initial Date of Deposit-December 1, 2022

COMMON STOCKS (101.05%):
Percentage Number Market Cost of
Ticker Symbol and of Aggregate of Value Securities to
Name of Issuer of Common Stocks (1)(4) Offering Price Shares per Share the Trust (3)
______________________________________ ______________ ______ _________ _____________
Consumer Staples (32.87%):
ADM Archer-Daniels-Midland Company 4.26% 800 $ 97.50 $ 78,000
BTI British American Tobacco Plc (ADR) + 4.28% 1,900 41.27 78,413
KO The Coca-Cola Company 4.51% 1,300 63.61 82,693
STZ Constellation Brands, Inc. (Class A) 4.22% 300 257.35 77,205
COST Costco Wholesale Corporation 2.94% 100 539.25 53,925
MDLZ Mondelez International, Inc. 4.43% 1,200 67.61 81,132
PG The Procter & Gamble Company 4.07% 500 149.16 74,580
WMT Walmart, Inc. 4.16% 500 152.42 76,210
Health Care (46.56%):
ABBV AbbVie Inc. 4.40% 500 161.18 80,590
CI Cigna Corporation 3.59% 200 328.89 65,778
CVS CVS Health Corporation 3.89% 700 101.88 71,316
DHR Danaher Corporation 4.48% 300 273.41 82,023
ELV Elevance Health Inc. 2.91% 100 532.92 53,292
LLY Eli Lilly and Company 4.05% 200 371.08 74,216
MCK McKesson Corporation 4.17% 200 381.68 76,336
NVO Novo Nordisk A/S (ADR) + 4.08% 600 124.60 74,760
PFE Pfizer Inc. 4.38% 1,600 50.13 80,208
REGN Regeneron Pharmaceuticals, Inc. * 4.10% 100 751.70 75,170
TMO Thermo Fisher Scientific Inc. 3.06% 100 560.22 56,022
VRTX Vertex Pharmaceuticals Incorporated * 3.45% 200 316.40 63,280
Utilities (21.62%):
AEP American Electric Power Company, Inc. 4.23% 800 96.80 77,440
EXC Exelon Corporation 4.29% 1,900 41.37 78,603
NEE NextEra Energy, Inc. 4.16% 900 84.70 76,230
NRG NRG Energy, Inc. 4.40% 1,900 42.45 80,655
SRE Sempra Energy 4.54% 500 166.19 83,095
_______ __________
Total Common Stocks 101.05% $1,851,172
======= ==========

Page 7

Schedule of Investments (cont'd.)

Defensive Equity Buy-Write Portfolio Series
FT 10412

At the Opening of Business on the Initial Date of Deposit-December 1, 2022

TREASURY OBLIGATIONS (4.73%):
Percentage Market Cost of
of Aggregate Value Securities to
Name of Issuer and Title of Treasury Obligation (1) Offering Price Par Value per Share the Trust (3)
___________________________________________________ ______________ _________ _________ _____________
U.S. Treasury Note, 2.500%, due March 31, 2023 1.19% $22,000 N.A. $ 21,853
U.S. Treasury Note, 2.625%, due June 30, 2023 1.19% 22,000 N.A. 21,749
U.S. Treasury Note, 2.875%, due September 30, 2023 1.18% 22,000 N.A. 21,669
U.S. Treasury Note, 2.250%, due December 31, 2023 1.17% 22,000 N.A. 21,438
Total Treasury Securities: _______ __________
Total Treasury Securities 4.73% $ 86,709
_______ __________
Total Investment in Securities 105.78% $1,937,881
======= ==========
LONG TERM EQUITY ANTICIPATION SECURITIES ("LEAPS(R)") (-5.78%) (2):
Strike Percentage Number Market Proceeds
Price of Aggregate of Value per to
Description of Call Options (1) per Share Offering Price Contracts Contract the Trust (3)
_______________________________ _________ ______________ _________ _________ _____________
WRITTEN OPTIONS (-5.78%):
Consumer Staples (-1.36%):
Archer-Daniels-Midland Company $115.00 (0.29)% 8 $ 660.00 $ (5,280)
British American Tobacco Plc (ADR) 50.00 (0.09)% 19 82.00 (1,558)
The Coca-Cola Company 75.00 (0.11)% 13 150.00 (1,950)
Constellation Brands, Inc. (Class A) 300.00 (0.22)% 3 1,370.00 (4,110)
Costco Wholesale Corporation 620.00 (0.21)% 1 3,855.00 (3,855)
Mondelez International, Inc. 80.00 (0.14)% 12 220.00 (2,640)
The Procter & Gamble Company 175.00 (0.13)% 5 480.00 (2,400)
Walmart, Inc. 180.00 (0.17)% 5 625.00 (3,125)
Health Care (-3.23%):
AbbVie Inc. 190.00 (0.19)% 5 700.00 (3,500)
Cigna Corporation 380.00 (0.25)% 2 2,260.00 (4,520)
CVS Health Corporation 120.00 (0.20)% 7 527.00 (3,689)
Danaher Corporation 320.00 (0.36)% 3 2,170.00 (6,510)
Elevance Health Inc. 620.00 (0.18)% 1 3,370.00 (3,370)
Eli Lilly and Company 430.00 (0.35)% 2 3,232.00 (6,464)
McKesson Corporation 450.00 (0.31)% 2 2,800.00 (5,600)
Novo Nordisk A/S (ADR) 145.00 (0.31)% 6 952.00 (5,712)
Pfizer Inc. 60.00 (0.20)% 16 225.00 (3,600)
Regeneron Pharmaceuticals, Inc. 880.00 (0.38)% 1 6,888.00 (6,888)
Thermo Fisher Scientific Inc. 650.00 (0.25)% 1 4,650.00 (4,650)
Vertex Pharmaceuticals Incorporated 380.00 (0.25)% 2 2,258.00 (4,516)
Utilities (-1.19%):
American Electric Power Company, Inc. 115.00 (0.14)% 8 320.00 (2,560)
Exelon Corporation 47.00 (0.26)% 19 250.00 (4,750)
NextEra Energy, Inc. 97.50 (0.28)% 9 575.00 (5,175)
NRG Energy, Inc. 50.00 (0.32)% 19 310.00 (5,890)
Sempra Energy 195.00 (0.19)% 5 710.00 (3,550)
_______ __________
Total Investment in LEAPS(R) (5.78)% $(105,862)
======= ==========

___________

See "Notes to Schedule of Investments" on page 9.

Page 8

NOTES TO SCHEDULE OF INVESTMENTS

(1) All Securities are represented by regular way contracts to purchase such
Securities which are backed by an irrevocable letter of credit deposited with
the Trustee. The Sponsor entered into purchase contracts for the Securities on
November 30, 2022. Such purchase contracts are expected to settle within two
business days.

(2) The LEAPS(R) can be exercised on any business day prior to their
expiration on January 19, 2024. Each contract entitles the holder thereof to
purchase 100 shares of common stock at the strike price. The LEAPS(R) call
options are accounted for at market value, and are not accounted for as
hedging instruments. LEAPS(R) call options can be volatile and involve certain
risks. The LEAPS(R) call options could result in a reduction of the total
return of the Trust. The notional value of each LEAPS(R) call option equals
the value of the corresponding common stock.

(3) The cost or proceeds of the Securities to the Trust represents the
aggregate underlying value with respect to the Securities acquired (generally
determined by the closing sale prices of the listed Securities and the ask
prices of over-the-counter traded Securities at the Evaluation Time on the
business day prior to the Initial Date of Deposit). The cost of Securities to
the Trust may not compute due to rounding the market value per share. The
offering side price of the Treasury Obligations is greater than the bid side
price of the Treasury Obligations which is the basis on which the Redemption
Price per Unit will be determined. The Sponsor valued the LEAPS(R) at their
last closing sale price (or closing bid price if there is no closing sale
price) at the Evaluation Time on the business day preceding the Initial Date
of Deposit. The value of the Securities, based on the bid side price of the
Treasury Obligations, the value of the Common Stocks, net of the value or ask
price of the LEAPS(R), is $1,832,001 (unaudited). The valuation of the
Securities has been determined by the Sponsor. In accordance with Financial
Accounting Standards Board Accounting Standards Codification 820 ("ASC 820"),
"Fair Value Measurement," fair value is defined as the price that the Trust
would either receive upon selling an investment or pay to transfer an options
liability to an independent buyer in a timely transaction in the principal or
most advantageous market of the investment. ASC 820 established a three-tier
hierarchy to maximize the use of the observable market data and minimize the
use of unobservable inputs and to establish classification of the fair value
measurements for disclosure purposes. Inputs refer broadly to the assumptions
that market participants would use in pricing the asset or liability,
including the technique or pricing model used to measure fair value and the
risk inherent in the inputs to the valuation technique. Inputs may be
observable or unobservable. Observable inputs are inputs that reflect the
assumptions market participants would use in pricing the asset or liability,
developed based on market data obtained from sources independent of the
reporting entity. Unobservable inputs are inputs that may reflect the
reporting entity's own assumptions about the assumptions market participants
would use in pricing the asset or liability, developed based on the best
information available in the circumstances. The three-tier hierarchy of inputs
is summarized in the three broad levels: Level 1 which represents quoted
prices in active markets for identical investments; Level 2 which represents
fair value based on other significant observable inputs (including, quoted
prices for similar investments in active markets, quoted prices for identical
or similar investments in markets that are non-active, inputs other than
quoted prices that are observable for the investment (for example, interest
rates and yield curves observable at commonly quoted intervals, volatilities,
prepayment speeds, loss severities, credit risks, and default rates) or inputs
that are derived from or corroborated by observable market data by correlation
or other means), and Level 3 which represents fair value based on significant
unobservable inputs (including the Trust's own assumptions in determining the
fair value of investments). The Trust's investments in Common Stocks of
$1,851,172 and LEAPS(R) of $(33,607) are classified as Level 1, which refers
to securities traded in an active market. The Trust's investments in Treasury
Obligations of $86,709 and LEAPS(R) of $(72,255) are classified as Level 2,
whose valuations on the date of deposit were determined by the Sponsor using
offering prices provided by third-party pricing services. The inputs used by
these third party pricing services were based upon significant observable
inputs that included, but were not limited to, the items noted above. The cost
of the Securities to the Sponsor, including accrued interest, and the
Sponsor's loss (which is the difference between the cost of the Securities to
the Sponsor and the cost of the Securities to the Trust) are $1,833,594 and
$925, respectively.

(4) Common Stocks of companies headquartered or incorporated outside the
United States comprise approximately 8.36% of the investments of the Trust
(consisting of Denmark, 4.08% and United Kingdom, 4.28%).

+ This Security represents the common stock of a foreign company which trades
through an American Depositary Receipt/ADR on the over-the-counter market or on
a U.S. national securities exchange.

* This Security represents a non-income producing security.

Page 9

The FT Series

The FT Series Defined.

We, First Trust Portfolios L.P. (the "Sponsor"), have created hundreds of
similar yet separate series of a unit investment trust which we have named the
FT Series. The series to which this prospectus relates, FT 10412, consists of
a single portfolio known as Defensive Equity Buy-Write Portfolio Series.

The Trust was created under the laws of the State of New York by a Trust
Agreement (the "Indenture") dated the Initial Date of Deposit. This agreement,
entered into among First Trust Portfolios L.P., as Sponsor, The Bank of New
York Mellon as Trustee and First Trust Advisors L.P. as Portfolio Supervisor,
governs the operation of the Trust.

YOU MAY GET MORE SPECIFIC DETAILS CONCERNING THE NATURE, STRUCTURE AND RISKS
OF THIS PRODUCT IN AN "INFORMATION SUPPLEMENT" BY CALLING THE SPONSOR AT 800-
621-1675, DEPT. CODE 2.

How We Created the Trust.

On the Initial Date of Deposit, we deposited a portfolio of Treasury
Obligations and Common Stocks (which Common Stocks are subject to the
LEAPS(R)) (collectively, the "Securities") with the Trustee and, in turn, the
Trustee delivered documents to us representing our ownership of the Trust in
the form of units ("Units"). Because the Common Stocks held by the Trust are
subject to the LEAPS(R), the Common Stocks' upside potential will be limited.
The Securities were deposited at prices equal to their market value as
determined by the Sponsor, which value has been reduced to reflect the Trust's
obligation under the LEAPS(R).

After the Initial Date of Deposit, we may deposit additional Securities in the
Trust, or cash (including a letter of credit or the equivalent) with
instructions to buy more Securities, to create new Units for sale. Any
additional Common Stocks deposited will be subject to the LEAPS(R) with the
same terms as the LEAPS(R) initially deposited. If we create additional Units,
we will attempt, to the extent practicable, to maintain the percentage
relationship established among the Securities on the Initial Date of Deposit
(as set forth under "Schedule of Investments"), adjusted to reflect the sale,
redemption or liquidation of any of the Securities or any stock split or a
merger or other similar event affecting the issuer of the Securities.

Since the prices of the Securities will fluctuate daily, the ratio of
Securities in the Trust, on a market value basis, will also change daily. The
portion of Securities represented by each Unit will not change as a result of
the deposit of additional Securities or cash in the Trust. If we deposit cash,
you and new investors may experience a dilution of your investment. This is
because prices of Securities will fluctuate between the time of the cash
deposit and the purchase of the Securities, and because the Trust pays the
associated brokerage fees. To reduce this dilution, the Trust will try to buy
the Securities as close to the Evaluation Time and as close to the evaluation
price as possible. In addition, because the Trust pays the brokerage fees
associated with the creation of new Units and with the sale of Securities to
meet redemption and exchange requests, frequent redemption and exchange
activity will likely result in higher brokerage expenses.

An affiliate of the Trustee may receive these brokerage fees or the Trustee
may retain and pay us (or our affiliate) to act as agent for the Trust to buy
Securities. If we or an affiliate of ours act as agent to the Trust, we will
be subject to the restrictions under the Investment Company Act of 1940, as
amended (the "1940 Act"). When acting in an agency capacity, we may select
various broker/dealers to execute securities transactions on behalf of the
Trust, which may include broker/dealers who sell Units of the Trust. We do not
consider sales of Units of the Trust or any other products sponsored by First
Trust as a factor in selecting such broker/dealers.

We cannot guarantee that the Trust will keep its present size and composition
for any length of time. Common Stocks may be called pursuant to the LEAPS(R)
prior to the Mandatory Termination Date or Securities may be periodically sold
under certain circumstances to satisfy Trust obligations, to meet redemption
requests and, as described in "Removing Securities from the Trust," to
maintain the sound investment character of the Trust, and the proceeds
received by the Trust will be used to meet Trust obligations or distributed to
Unit holders. However, Securities will not be sold to take advantage of market
fluctuations or changes in anticipated rates of appreciation or depreciation,
or if they no longer meet the criteria by which they were selected. You will
not be able to dispose of or vote any of the Securities in the Trust. As the
holder of the Securities, the Trustee will vote the Securities and, except as
described in "Removing Securities from the Trust," will endeavor to vote the
Securities such that the Securities are voted as closely as possible in the
same manner and the same general proportion as are the Securities held by
owners other than such Trust.

Page 10

Neither we nor the Trustee will be liable for a failure in any of the
Securities. However, if a contract for the purchase of any of the Securities
initially deposited in the Trust fails, unless we can purchase substitute
Securities ("Replacement Securities") we will refund to you that portion of
the purchase price and transactional sales charge resulting from the failed
contract on the next Income Distribution Date. Any Replacement Security the
Trust acquires will be identical to those from the failed contract.

Portfolio

Objectives.

The Trust seeks income, with limited capital appreciation as a secondary
objective. Under normal circumstances, the Trust will invest at least 80% of
its assets in equity securities. The Trust is concentrated (i.e., invests more
than 25% of Trust assets) in stocks of companies within each of the consumer
staples and health care sectors.

Portfolio Selection Process.

The Trust is a unit investment trust which invests in a fixed portfolio of
Common Stocks of companies in the consumer staples, health care, and utilities
sectors. The Sponsor believes products and services offered by companies in
these sectors will continue to be attractive to consumers, as these companies
have demonstrated strong fiscal health and exhibited less volatility and
downside risk in times of economic downturns.

An initial universe is created by identifying companies with significant
business operations in the consumer staples, health care or utilities sectors.
Only U.S.-listed common stocks and American Depositary Receipts (ADRs) that
have adequate liquidity for investment are eligible for selection.

Our selection process begins by examining the historical financial results of
the stocks from the initial universe. The stocks are then evaluated using
fundamental factors such as sales, earnings and cash flow growth; valuation
factors such as price/earnings, price/cash flow, price/sales and price/book;
and technical factors such as price momentum and earnings surprises.

A team of equity analysts also consider how the stocks will perform in the
future by calculating an estimated value for each of the companies utilizing a
Cash Flow Return on Investment ("CFROI") method. The CFROI method compares an
estimate of a company's internal rate of return against an estimate of a
company's cost of capital. Companies that generate returns in excess of their
capital costs are favored over companies that do not. A secondary valuation is
also made employing a concept called Economic Margin ("EM"). EM measures the
return a company earns versus its cost of capital to determine if a company is
generating wealth. The analysts use the estimated valuations calculated by the
CFROI and EM methods to determine which companies are trading at an attractive
market price relative to their estimated value. These companies are favored
for inclusion in the Trust over companies that do not.

The final portfolio is then selected by the equity analysts who evaluate each
stock by examining the stock's relative valuation and other qualitative
factors such as third-party analyst ratings, competitive advantages and
quality of management.

After considering the above factors together, the equity analysts make a final
determination and select the stocks with the best prospects to meet the
investment objectives, that trade at attractive valuations, and, in the
opinion of the analysts, are likely to exceed market expectations of future
cash flows.

Simultaneously, the portfolio sells a LEAPS(R) call option against each Common
Stock (which is known as a "buy-write" or "covered call" strategy). The
writing (selling) of a call option generates income in the form of a premium
paid by the option buyer. The portfolio invests this income in U.S. Treasury
notes and the interest received from the notes is paid to Unit holders
periodically.

Each Common Stock is subject to a contractual right, in the form of LEAPS(R),
which gives the holder of the LEAPS(R) (the "Right Holder") the right to buy
the Common Stock at a predetermined price (the "Strike Price") on any business
day prior to the expiration of the LEAPS(R). Each LEAPS(R) will be issued by
The Options Clearing Corporation ("OCC") in the form of an American style
option, which means that it is exercisable at the Strike Price on any business
day prior to its expiration date. The expiration date for each of the LEAPS(R)
included in the Trust is January 19, 2024.

The Treasury Obligations included in the Trust are non-callable debt
obligations that are issued by and backed by the full faith and credit of the
U.S. Government.

In calculating the net asset value of a Unit, the price of a Unit is reduced
by the value of the LEAPS(R).

As of the close of business on the business day preceding the Initial Date of
Deposit, the capital appreciation on the Common Stocks held by the Trust is
limited to a maximum of approximately 19.30%, because of the obligation of the

Page 11

Trust to the Right Holder with respect to each of the Common Stocks entitling
the Right Holder to purchase the Common Stocks at the Strike Price. The
LEAPS(R) limit the Trust's upside potential in the Common Stocks to an amount
equal to the Strike Price. However, as the option premium received in return
for issuing the LEAPS(R) was used to purchase Treasury Obligations, the Trust
will receive interest from the Treasury Obligations until they mature and the
principal from the Treasury Obligations shortly after they mature.

Illustrative Market Scenarios.

Stock prices increase above the LEAPS'(R) exercise price: If the market price
of a Common Stock held by the Trust is greater than its Strike Price, the
Trust will not participate in any appreciation in that Common Stock above the
Strike Price because it is expected that the holder of the related LEAPS(R)
will exercise its right to purchase that Common Stock from the Trust at the
Strike Price. Profits are limited to the premium income received from writing
the LEAPS(R), dividends received from the Common Stocks before the date the
option to purchase is exercised, interest received from the U.S. Treasury
Obligations, plus the difference between each Common Stock's initial price and
their strike price. The Trust will forgo any dividends paid on the Common
Stocks after the date the option to purchase is exercised and any gain in the
underlying stock price after the stock is sold. It is important to note that
writing covered calls limits the appreciation potential of the underlying
Common Stocks.

Stock prices remain stable or increase to a level below the LEAPS'(R) exercise
price: If the market price of a Common Stock held by the Trust remains stable
or increases in value but fails to appreciate to a price equal to the related
Strike Price, it is expected that the LEAPS(R) will terminate without being
exercised, and the Trust, in connection with its termination, will liquidate
the Common Stock at its then current market value. Profits are limited to the
premium income received from writing the LEAPS(R), plus capital appreciation
and dividends from the Common Stocks, if any, as well as interest received
from the U.S. Treasury Obligations.

Stock prices decrease: If the market price of a Common Stock held by the Trust
decreases, it is expected that the LEAPS(R) will terminate without being
exercised, and the Trust, in connection with its termination, will liquidate
the Common Stock at its then current market value, which will be less than the
value on the Initial Date of Deposit. However, the premium income received
from writing the LEAPS(R) lowers the breakeven point on the common stocks
(i.e., the point at which the market price is equal to the original cost) by
effectively reducing the common stocks' original cost. Losses from the
decrease in value of the Common Stocks are limited by the premium income
received from the LEAPS(R), dividends received from the Common Stocks and
interest received from the U.S. Treasury Obligations.

The Strike Price for a Common Stock held by the Trust will be adjusted
downward (but not below zero) upon certain extraordinary distributions made by
the issuers of the Common Stocks to Unit holders before the LEAPS'(R)
expiration triggered by certain corporate events affecting such Common Stock.
For each market scenario, a downward adjustment to the Strike Price for a
Common Stock will have the effect of reducing the equity appreciation that a
Unit holder may receive. See "Risk Factors-LEAPS(R)."

Additional Portfolio Contents.

In addition to the investments described above, the Trust invests in: dividend-
paying securities, foreign securities and companies with various market
capitalizations.

As with any similar investment, there can be no guarantee that the objectives
of the Trust will be achieved. See "Risk Factors" for a discussion of the
risks of investing in the Trust.

Risk Factors

Price Volatility. The Trust invests in Treasury Obligations, Common Stocks and
LEAPS(R) for each of the Common Stocks. The value of the Trust's Units will
fluctuate with changes in the value of the Treasury Obligations, Common Stocks
and LEAPS(R).

Because the Trust is not managed, the Trustee will not sell stocks in response
to or in anticipation of market fluctuations, as is common in managed
investments. As with any investment, we cannot guarantee that the performance
of the Trust will be positive over any period of time, or that you won't lose
money. Units of the Trust are not deposits of any bank and are not insured or
guaranteed by the Federal Deposit Insurance Corporation or any other
government agency.

Market Risk. Market risk is the risk that a particular security, or Units of
the Trust in general, may fall in value. Securities are subject to market
fluctuations caused by such factors as economic, political, regulatory or
market developments, changes in interest rates and perceived trends in
securities prices. Units of the Trust could decline in value or underperform
other investments. In addition, local, regional or global events such as war,
acts of terrorism, spread of infectious diseases or other public health
issues, recessions, political turbulence or other events could have a

Page 12

significant negative impact on the Trust and its investments. Such events may
affect certain geographic regions, countries, sectors and industries more
significantly than others. Such events could adversely affect the prices and
liquidity of the Trust's portfolio securities and could result in disruptions
in the trading markets. Any such circumstances could have a materially
negative impact on the value of the Trust's Units and result in increased
market volatility.

In February 2022, Russia commenced a military attack on Ukraine. In response,
various countries, including the United States, issued broad-ranging sanctions
on Russia and certain Russian companies and individuals. The hostilities
between the two countries may escalate and any existing or future sanctions
could have a severe adverse effect on Russia's economy, currency, companies
and region as well as negatively impact other regional and global economic
markets of the world, companies in such countries and various sectors,
industries and markets for securities and commodities globally, such as oil
and natural gas, and may have a negative effect on a Trust's investments and
performance beyond any direct exposure to Russian issuers or those of
adjoining geographic regions. Russia may also take retaliatory actions or
countermeasures, such as cyberattacks and espionage, which may negatively
impact the countries and companies in which the Trust may invest. The extent
and duration of the military action or future escalation of such hostilities;
the extent and impact of existing and any future sanctions, market disruptions
and volatility; and the result of any diplomatic negotiations cannot be
predicted. These and any related events could have a significant negative
impact on certain of the Trust's investments as well as the Trust's
performance, and the value or liquidity of certain Securities held by the
Trust may decline significantly.

An outbreak of a respiratory disease designated as COVID-19 was first detected
in China in December 2019. The COVID-19 global pandemic and the ensuing
policies enacted by governments and central banks have caused and may continue
to cause significant volatility and uncertainty in global financial markets,
negatively impacting global growth prospects. While the U.S. has resumed
"reasonably" normal business activity, many countries continue to impose
lockdown measures. The duration of the COVID-19 outbreak and its effects
cannot be determined with certainty and may exacerbate other pre-existing
political, social and economic risks. Additionally, there is no guarantee that
vaccines will be effective against emerging variants of the disease.

Governments and central banks, including the Federal Reserve, have taken
extraordinary and unprecedented actions to support local and global economies
and financial markets. These measures have included, among other policy
responses, a $700 billion quantitative easing program, a reduction of the
Federal funds rate to near-zero, and numerous economic stimulus packages. The
impact of these and additional measures taken in the future, and whether they
will be effective in mitigating economic and market disruptions, including
upward pressure on prices, will not be known for some time. As a means to
fight inflation, the Federal Reserve has raised interest rates and expects to
continue to do so and has announced that it intends to reverse previously
implemented quantitative easing.

Common Stocks. The Trust invests in shares of Common Stocks. Common stock
prices fluctuate for several reasons including changes in investors'
perceptions of the financial condition of an issuer or the general condition
of the relevant stock market, such as the current market volatility, or when
political or economic events affecting the issuers occur. In addition, common
stock prices may be particularly sensitive to rising interest rates, as the
cost of capital rises and borrowing costs increase, negatively impacting
issuers.

U.S. Treasury Obligations. The Trust invests in U.S. Treasury obligations.
U.S. Treasury obligations are direct obligations of the United States which
are backed by the full faith and credit of the United States. The value of the
Treasury Obligations will be adversely affected by decreases in bond prices
and increases in interest rates. Certain Treasury Obligations may have been
purchased on the Initial Date of Deposit at prices of less than their par
value at maturity, indicating a market discount. Other Treasury Obligations
may have been purchased on the Initial Date of Deposit at prices greater than
their par value at maturity, indicating a market premium. The coupon interest
rate of Treasury Obligations purchased at a market discount was lower than
current market interest rates of newly issued bonds of comparable rating and
type and the coupon interest rate of Treasury Obligations purchased at a
market premium was higher than current market interest rates of newly issued
bonds of comparable rating and type. Generally, the value of bonds purchased
at a market discount will increase in value faster than bonds purchased at a
market premium if interest rates decrease. Conversely, if interest rates
increase, as we are currently experiencing, the value of bonds purchased at a
market discount will decrease faster than bonds purchased at a market premium.

Page 13

LEAPS(R). The Common Stocks held by the Trust are subject to LEAPS(R). The
value of the LEAPS(R) may be adversely affected if the market for LEAPS(R)
becomes less liquid or smaller. If this occurs, there will likely be a
negative impact on the value of your Units. Although you may redeem your Units
at any time, if you redeem before the LEAPS(R) are exercised or expire, the
value of your Units may be adversely affected by the value of the LEAPS(R).
However, if LEAPS(R) are not exercised and you hold your Units until the
scheduled Termination Date, the LEAPS(R) will have ceased to exist and the
Trust's portfolio will consist of only cash or Common Stocks or a combination
of each.

If you sell or redeem your Units before the LEAPS(R) are exercised, or if the
Trust terminates prior to its scheduled Termination Date and the LEAPS(R) have
not been exercised, you may not realize any appreciation in the value of the
Common Stocks because even if the Common Stocks appreciate in value, that
appreciation may be more than fully, fully or partly offset by an increase in
value in the LEAPS(R). The value of the LEAPS(R) is deducted from the value of
the Trust's assets when determining the value of a Unit. If the Common Stocks
decline in price, your loss may be greater than it would be if there were no
LEAPS(R) because the value of the LEAPS(R) is a reduction to the value of the
Common Stocks when calculating the value of a Unit. An increase in value of
the LEAPS(R), an obligation of the Trust to sell or deliver the Common Stocks
at the Strike Price if the LEAPS(R) are exercised by the Right Holder, will
reduce the value of the Common Stocks in the Trust, below the value of the
Common Stocks that would otherwise be realizable if the Common Stocks were not
subject to the LEAPS(R). You should note that even if the price of a Common
Stock does not change, if the value of a LEAPS(R) increases (for example,
based on increased volatility of a Common Stock) your Unit will lose value.

The value of the LEAPS(R) reduces the value of your Units. As the value of the
LEAPS(R) increases, it has a more negative impact on the value of your Units.
The value of the LEAPS(R) will also be affected by changes in the value and
dividend rates of the Common Stocks, an increase in interest rates, a change
in the actual and perceived volatility of the stock market and the Common
Stocks and the remaining time to expiration. Additionally, the value of a
LEAPS(R) does not increase or decrease at the same rate as the underlying
stock (although they generally move in the same direction). However, as a
LEAPS(R) approaches its expiration date, its value increasingly moves with the
price of the Common Stock subject to the LEAPS(R).

The Strike Price for each LEAPS(R) held by the Trust may be adjusted downward
before the LEAPS(R) expiration triggered by certain corporate events affecting
that Common Stock. A downward adjustment to the Strike Price will have the
effect of reducing the equity appreciation that a Unit holder may receive. If
the Strike Price is adjusted downward and the LEAPS(R) is exercised at the
reduced Strike Price, a Unit Holder would lose money if the value of the
Common Stock at the time that the Unit is purchased is greater than the
adjusted Strike Price. Adjustments will be made to the Strike Price of a
Common Stock based on adjustments made by the OCC to options on that security.
The OCC generally does not adjust option strike prices to reflect ordinary
dividends but may adjust option strike prices to reflect certain corporate
events such as extraordinary dividends, stock splits, merger or other
extraordinary distributions or events.

If the value of the underlying Common Stocks exceeds the Strike Price of the
LEAPS(R), it is likely that the Right Holder will exercise their right to
purchase the Common Stocks subject to the LEAPS(R) from the Trust. As the
LEAPS(R) may be exercised on any business day prior to their expiration,
Common Stocks may be sold to the Right Holders of the LEAPS(R) prior to the
termination of the Trust. If this occurs, distributions from the Trust will be
reduced by the amount of the dividends which would have been paid by Common
Stocks sold from the Trust. As discussed in "Tax Matters," the sale of Common
Stocks from the Trust will likely result in capital gains to Unit holders,
which may be short-term depending on the holding period of the Common Stocks.
In addition, the sale of Common Stocks may, in certain circumstances, result
in the early termination of the Trust.

You should be aware that a product which includes writing call options (i.e.,
LEAPS(R)) may not be suitable for all investors. It may not be appropriate for
investors seeking above-average capital appreciation. Before investing, you
should make sure you understand the risks of this type of product, and whether
it suits your current financial objectives.

Distributions. Certain of the Common Stocks held by the Trust may currently
pay dividends, but there is no guarantee that the issuers of the Common Stocks
will declare dividends in the future or that, if declared, they will either
remain at current levels or increase over time. In addition, there is no
guarantee that the U.S. Government will be able to satisfy its interest
payment obligations to the Trust over the life of the Trust.

Page 14

Concentration Risk. When at least 25% of a trust's portfolio is invested in
securities issued by companies within a single sector, the trust is considered
to be concentrated in that particular sector. A portfolio concentrated in one
or more sectors may present more risks than a portfolio broadly diversified
over several sectors.

The Trust is concentrated in stocks of companies within each of the consumer
staples and health care sectors.

Consumer Staples. Consumer staples companies provide products directly to the
consumer that are typically considered non-discretionary items based on
consumer purchasing habits. Such products include food, beverages, household
items and tobacco. Companies providing these products may be affected by the
regulation of various product components and production methods, new laws,
regulations or litigation, marketing campaigns, competitive pricing,
enumerated factors, consumer confidence, materials costs and other factors
affecting consumer demand. Changes in the worldwide economy, demographics,
consumer preferences, consumer spending, exploration and production spending
may adversely affect these companies, as well as natural and man-made
disasters, political, social or labor unrest, world events and economic
conditions. Historically, the demand for consumer staples goods has remained
fairly constant regardless of the state of the economy. With some products,
such as food, alcohol and tobacco, demand sometimes increases during economic
downturns. However, price competition among suppliers may be very challenging,
which can drive prices lower and impact returns.

Health Care. General risks of health care companies include extensive
competition, generic drug sales resulting from the loss of patent protection,
product liability litigation and evolving government regulation. Research and
development costs of bringing new drugs to market are substantial, and there
is no guarantee that a product will ever come to market. Health care facility
operators may be affected by the demand for services, the ability of the
facility to provide the services required, efforts by government or insurers
to limit rates, restriction of government financial assistance and competition
from other providers. The health care sector may be impacted if Congress
proposes legislation regarding reform on the health care sector, changes in
current laws regarding access to health insurance and the overall risks and
costs of compliance with such regulations. Whether these proposals will be
adopted and their possible long-term effects on the health care industry
remains uncertain and cannot be predicted. In addition, health crises, such as
a pandemic outbreak, can severely impact the health care industry in
particular. These crises can disrupt health care services and processes,
strain resources and supplies, and are often increasingly difficult to assess
and impossible to predict.

Utilities. The Trust invests in utilities companies. General problems of
utility companies include risks of increases in fuel and other operating
costs; restrictions on operations and increased costs and delays as a result
of environmental, nuclear safety and other regulations; regulatory
restrictions on the ability to pass increasing wholesale costs along to the
retail and business customer; energy conservation; technological innovations
which may render existing plants, equipment or products obsolete; the effects
of local weather, maturing markets and difficulty in expanding to new markets
due to regulatory and other factors; natural or man-made disasters; difficulty
obtaining adequate returns on invested capital; the high cost of obtaining
financing during periods of inflation; difficulties of the capital markets in
absorbing utility debt and equity securities; and increased competition. In
addition, taxes, government regulation, international politics, price and
supply fluctuations, and volatile interest rates and energy conservation may
cause difficulties for utilities. All of such issuers have been experiencing
certain of these problems in varying degrees.

Utility companies are subject to extensive regulation at the federal and state
levels in the United States. The value of utility company securities may
decline as a result of changes to governmental regulation controlling the
utilities sector. Adverse regulatory changes could prevent or delay utilities
from passing along cost increases to customers, which could hinder a utility's
ability to meet its obligations to its suppliers.

Furthermore, regulatory authorities, which may be subject to political and
other pressures, may not grant future rate increases, or may impose accounting
or operational policies, any of which could affect a company's profitability
and the value of its securities. In addition, federal, state and municipal
governmental authorities may review existing, and impose additional,
regulations governing the licensing, construction and operation of nuclear
power plants.

Foreign Securities. Certain of the Common Stocks held by the Trust are issued
by foreign entities, which makes the Trust subject to more risks than if it
invested solely in domestic securities. Risks of foreign securities include
higher brokerage costs; different accounting standards; expropriation,
nationalization or other adverse political or economic developments; currency

Page 15

devaluations, blockages or transfer restrictions; restrictions on foreign
investments and exchange of securities; inadequate financial information; lack
of liquidity of certain foreign markets; and less government supervision and
regulation of exchanges, brokers, and issuers in foreign countries. Certain
foreign markets have experienced heightened volatility due to recent negative
political or economic developments or natural disasters. Securities issued by
non-U.S. issuers may pay dividends in foreign currencies and may be
principally traded in foreign currencies. Therefore, there is a risk that the
U.S. dollar value of these dividend payments and/or securities will vary with
fluctuations in foreign exchange rates.

American Depositary Receipts/ADRs and similarly structured securities may be
less liquid than the underlying shares in their primary trading market. Any
distributions paid to the holders of depositary receipts are usually subject
to a fee charged by the depositary. Issuers of depositary receipts are not
obligated to disclose information that is considered material in the United
States. As a result, there may be less information available regarding such
issuers. Holders of depositary receipts may have limited voting rights, and
investment restrictions in certain countries may adversely impact the value of
depositary receipts because such restrictions may limit the ability to convert
shares into depositary receipts and vice versa. Such restrictions may cause
shares of the underlying issuer to trade at a discount or premium to the
market price of the depositary receipts.

Interest Rate Risk. Interest rate risk is the risk that the value of the
Securities held by the Trust will fall if interest rates increase. Bonds
typically fall in value when interest rates rise and rise in value when
interest rates fall. Bonds with longer periods before maturity are often more
sensitive to interest rate changes. The Federal Reserve has recently raised
interest rates and expects to continue to do so in response to inflation.
Therefore, risks associated with rising rates are heightened for the
Securities held by the Trust.

Credit Risk. Credit risk is the risk that a security's issuer is unable or
unwilling to make dividend, interest or principal payments when due and the
related risk that the value of a security may decline because of concerns
about the issuer's ability or willingness to make such payments.

Bond Quality Risk. Bond quality risk is the risk that a bond will fall in
value if a rating agency decreases the bond's rating.

Liquidity Risk. Liquidity risk is the risk that the value of a bond will fall
if trading in the bond is limited or absent. No one can guarantee that a
liquid trading market will exist for any bond because these bonds generally
trade in the over-the-counter market (they are not listed on a securities
exchange).

Valuation Risk. Unlike publicly traded securities that trade on national
securities exchanges, there is no central place or exchange for trading most
debt securities. Debt securities generally trade on an "over-the-counter"
market. Due to the lack of centralized information and trading, the valuation
of debt securities may carry more uncertainty and risk than that of publicly
traded securities. Accordingly, determinations of the fair value of debt
securities may be based on infrequent and dated information. Also, because the
available information is less reliable and more subjective, elements of
judgment may play a greater role in valuation of debt securities than for
other types of securities.

Market Discount. Certain of the Securities held by the Trust may have current
market values which are below the principal value of such Securities on the
Initial Date of Deposit. A primary reason for the market value of such bonds
being less than principal value at maturity is that the interest rate of such
bonds is at lower rates than the current market interest rate for comparably
rated bonds. Bonds selling at market discounts tend to increase in market
value as they approach maturity. Because the Trust is not actively managed,
the Trustee will not sell bonds in response to or in anticipation of market
discounts or fluctuations.

On sale or redemption, Unit holders may receive ordinary income dividends from
the Trust if the Trust sells or redeems bonds that were acquired at a market
discount, or sells bonds at a short-term capital gain. In general, the
Internal Revenue Service will treat bonds as market discount bonds when the
cost of the bond, plus any original issue discount that has not yet accrued,
is less than the amount due to be paid at the maturity of the bond. Any gain
realized that is in excess of the earned portion of original issue discount
will be taxable as capital gain unless the gain is attributable to market
discount in which case the accretion of market discount is taxable as ordinary
income.

Small and/or Mid Capitalization Companies. One of the Common Stocks held by
the Trust is issued by a small and/or mid capitalization company. Investing in
stocks of such companies may involve greater risk than investing in larger
companies. For example, such companies may have limited product lines, as well
as shorter operating histories, less experienced management and more limited
financial resources than larger companies. Securities of such companies
generally trade in lower volumes and are generally subject to greater and less

Page 16

predictable changes in price than securities of larger companies. In addition,
small and mid-cap stocks may not be widely followed by the investment
community, which may result in low demand.

Large Capitalization Companies. Certain of the Common Stocks held by the Trust
are issued by large capitalization companies. The return on investment in
stocks of large capitalization companies may be less than the return on
investment in stocks of small and/or mid capitalization companies. Large
capitalization companies may also grow at a slower rate than the overall market.

Cybersecurity Risk. As the use of Internet technology has become more
prevalent in the course of business, the Trust has become more susceptible to
potential operational risks through breaches in cybersecurity. A breach in
cybersecurity refers to both intentional and unintentional events that may
cause the Trust to lose proprietary information, suffer data corruption or
lose operational capacity. Such events could cause the Sponsor of the Trust to
incur regulatory penalties, reputational damage, additional compliance costs
associated with corrective measures and/or financial loss. Cybersecurity
breaches may involve unauthorized access to digital information systems
utilized by the Trust through "hacking" or malicious software coding, but may
also result from outside attacks such as denial-of-service attacks through
efforts to make network services unavailable to intended users. In addition,
cybersecurity breaches of the Trust's third-party service providers, or
issuers in which the Trust invests, can also subject the Trust to many of the
same risks associated with direct cybersecurity breaches. The Sponsor of, and
third-party service provider to, the Trust have established risk management
systems designed to reduce the risks associated with cybersecurity. However,
there is no guarantee that such efforts will succeed, especially because the
Trust does not directly control the cybersecurity systems of issuers or third-
party service providers.

Legislation/Litigation. From time to time, various legislative initiatives are
proposed in the United States and abroad which may have a negative impact on
certain of the companies represented in the Trust. In addition, litigation
regarding the issuers of the Securities, or the industries represented by
these issuers, may negatively impact the value of these Securities. We cannot
predict what impact any pending or proposed legislation or pending or
threatened litigation will have on the value of the Securities.

Public Offering

The Public Offering Price.

Units will be purchased at the Public Offering Price, the price per Unit of
which is comprised of the following:

- The aggregate underlying value of the Treasury Obligations and the Common
Stocks, less the value of the LEAPS(R);

- The amount of any cash in the Income and Capital Accounts;

- Net interest accrued but unpaid on the Treasury Obligations after the First
Settlement Date to the date of settlement;

- Dividends receivable on the Common Stocks; and

- The maximum sales charge (which combines an initial upfront sales charge, a
deferred sales charge and the creation and development fee).

The price you pay for your Units will differ from the amount stated under
"Summary of Essential Information" due to various factors, including
fluctuations in the prices of the Securities and LEAPS(R) and changes in the
value of the Income and/or Capital Accounts.

Although you are not required to pay for your Units until two business days
following your order (the "date of settlement"), you may pay before then. You
will become the owner of Units ("Record Owner") on the date of settlement if
payment has been received. If you pay for your Units before the date of
settlement, we may use your payment during this time and it may be considered
a benefit to us, subject to the limitations of the Securities Exchange Act of
1934, as amended.

The number of Units available may be insufficient to meet demand. This may be
because of the Sponsor's inability to, or decision not to, purchase and
deposit underlying Securities in amounts sufficient to maintain the
proportionate numbers of shares of each Security as required to create
additional Units or because of its inability to sell LEAPS(R).

Organization Costs. Securities purchased with the portion of the Public
Offering Price intended to be used to reimburse the Sponsor for the Trust's
organization costs (including costs of preparing the registration statement,
the Indenture and other closing documents, registering Units with the SEC and
states, the initial audit of the Trust's statement of net assets, legal fees
and the initial fees and expenses of the Trustee) will be purchased in the
same proportionate relationship as all the Securities contained in the Trust.
Securities will be sold to reimburse the Sponsor for the Trust's organization

Page 17

costs at the end of the initial offering period (a significantly shorter time
period than the life of the Trust). During the initial offering period, there
may be a decrease in the value of the Securities. To the extent the proceeds
from the sale of these Securities are insufficient to repay the Sponsor for
Trust organization costs, the Trustee will sell additional Securities to allow
the Trust to fully reimburse the Sponsor. In that event, the net asset value
per Unit of the Trust will be reduced by the amount of additional Securities
sold. Although the dollar amount of the reimbursement due to the Sponsor will
remain fixed and will never exceed the per Unit amount set forth for the Trust
in "Notes to Statement of Net Assets," this will result in a greater effective
cost per Unit to Unit holders for the reimbursement to the Sponsor. To the
extent actual organization costs are less than the estimated amount, only the
actual organization costs will ultimately be charged to the Trust. When
Securities are sold to reimburse the Sponsor for organization costs, the
Trustee will sell Securities, to the extent practicable, which will maintain
the same proportionate relationship among the Securities contained in the
Trust as existed prior to such sale.

Accrued Interest.

Accrued interest represents unpaid interest on a Treasury Obligation from the
last day it paid interest. Interest on the Treasury Obligations is paid
monthly, although the Trust accrues such interest daily. Because the Trust
always has an amount of interest earned but not yet collected, the Public
Offering Price of Units will have added to it the proportionate share of
accrued interest to the date of settlement. You will receive the amount, if
any, of accrued interest you paid for on the next Distribution Date. In
addition, if you sell or redeem your Units you will be entitled to receive
your proportionate share of the accrued interest from the purchaser of your
Units.

Minimum Purchase.

The minimum amount per account you can purchase of the Trust is generally
$1,000 worth of Units ($500 if you are purchasing Units for your Individual
Retirement Account or any other qualified retirement plan), but such amounts
may vary depending on your selling firm.

Maximum Sales Charge.

The maximum sales charge of 1.85% per Unit is comprised of a transactional
sales charge and a creation and development fee. After the initial offering
period the maximum sales charge will be reduced by 0.50%, to reflect the
amount of the previously charged creation and development fee.

Transactional Sales Charge.

The transactional sales charge you will pay has both an initial and a deferred
component.

Initial Sales Charge. The initial sales charge, which you will pay at the time
of purchase, is equal to the difference between the maximum sales charge of
1.85% of the Public Offering Price and the sum of the maximum remaining
deferred sales charge and creation and development fee (initially $.185 per
Unit). On the Initial Date of Deposit, and any other day the Public Offering
Price per Unit equals $10.00, there is no initial sales charge. Thereafter,
you will pay an initial sales charge when the Public Offering Price per Unit
exceeds $10.00 and as deferred sales charge and creation and development fee
payments are made.

Monthly Deferred Sales Charge. In addition, three monthly deferred sales
charges of $.045 per Unit will be deducted from the Trust's assets on
approximately the twentieth day of each month from February 17, 2023 through
April 20, 2023. If you buy Units at a price of less than $10.00 per Unit, the
dollar amount of the deferred sales charge will not change, but the deferred
sales charge on a percentage basis will be more than 1.35% of the Public
Offering Price.

Creation and Development Fee.

As Sponsor, we will also receive, and the Unit holders will pay, a creation
and development fee. See "Expenses and Charges" for a description of the
services provided for this fee. The creation and development fee is a charge
of $.050 per Unit collected at the end of the initial offering period. If you
buy Units at a price of less than $10.00 per Unit, the dollar amount of the
creation and development fee will not change, but the creation and development
fee on a percentage basis will be more than 0.50% of the Public Offering Price.

Discounts for Certain Persons.

The maximum sales charge is 1.85% per Unit and the maximum dealer concession
is 1.25% per Unit.

If you are purchasing Units for an investment account, the terms of which
provide that your registered investment advisor or registered broker/dealer
(a) charges periodic fees in lieu of commissions; (b) charges for financial
planning, investment advisory or asset management services; or (c) charges a
comprehensive "wrap fee" or similar fee for these or comparable services ("Fee
Accounts"), you will not be assessed the transactional sales charge described
above on such purchases. These Units will be designated as Fee Account Units
and assigned a Fee Account CUSIP Number. Certain Fee Account Unit holders may
be assessed transaction or other account fees on the purchase and/or

Page 18

redemption of such Units by their registered investment advisor, broker/dealer
or other processing organizations for providing certain transaction or account
activities. Fee Account Units are not available for purchase in the secondary
market. We reserve the right to limit or deny purchases of Units not subject
to the transactional sales charge by investors whose frequent trading activity
we determine to be detrimental to the Trust.

Employees, officers and directors (and immediate family members) of the
Sponsor, our related companies, and dealers and their affiliates will purchase
Units at the Public Offering Price less the applicable dealer concession,
subject to the policies of the related selling firm. Immediate family members
include spouses, or the equivalent if recognized under local law, children or
step-children under the age of 21 living in the same household, parents or
step-parents and trustees, custodians or fiduciaries for the benefit of such
persons. Only employees, officers and directors of companies that allow their
employees to participate in this employee discount program are eligible for
the discounts.

You will be charged the deferred sales charge per Unit regardless of the price
you pay for your Units or whether you are eligible to receive any discounts.
However, if the purchase price of your Units was less than $10.00 per Unit or
if you are eligible to receive a discount such that the maximum sales charge
you must pay is less than the applicable maximum deferred sales charge,
including Fee Account Units, you will be credited additional Units with a
dollar value equal to the difference between your maximum sales charge and the
maximum deferred sales charge at the time you buy your Units. The dollar value
of these additional credited Units (as with all Units) will fluctuate over
time, and may be less on the dates deferred sales charges or the creation and
development fee are collected than their value at the time they were issued.

The Value of the Securities.

The Sponsor will determine the aggregate underlying value of the Securities
and LEAPS(R) in the Trust as of the Evaluation Time on each business day and
will adjust the Public Offering Price of the Units according to this
valuation. This Public Offering Price will be effective for all orders
received before the Evaluation Time on each such day. If we or the Trustee
receive orders for purchases, sales or redemptions after that time, or on a
day which is not a business day, they will be held until the next
determination of price. The term "business day" as used in this prospectus
shall mean any day on which the NYSE is open. For purposes of Securities and
Unit settlement, the term business day does not include days on which U.S.
financial institutions are closed.

The aggregate underlying value of the Treasury Obligations in the Trust will
be determined on the basis of current offering prices. The aggregate
underlying value of the Common Stocks in the Trust will be determined as
follows: if the Common Stocks are listed on a national or foreign securities
exchange or The NASDAQ Stock Market, LLC(R), their value shall generally be
based on the closing sale price on the exchange or system which is the
principal market therefore ("Primary Exchange"), which shall be deemed to be
the NYSE if the Common Stocks are listed thereon (unless the Sponsor deems
such price inappropriate as the basis for evaluation). In the event a closing
sale price on the Primary Exchange is not published, the Common Stocks will be
valued based on the last trade price on the Primary Exchange. If no trades
occur on the Primary Exchange for a specific trade date, the value will be
based on the closing sale price from, in the opinion of the Sponsor, an
appropriate secondary exchange, if any. If no trades occur on the Primary
Exchange or any appropriate secondary exchange on a specific trade date, the
Sponsor will determine the value of the Common Stocks using the best
information available to the Sponsor, which may include the prior day's
evaluated price. If the Common Stock is an American Depositary Receipt/ADR,
Global Depositary Receipt/GDR or other similar security in which no trade
occurs on the Primary Exchange or any appropriate secondary exchange on a
specific trade date, the value will be based on the evaluated price of the
underlying security, determined as set forth above, after applying the
appropriate ADR/GDR ratio, the exchange rate and such other information which
the Sponsor deems appropriate. For purposes of valuing Common Stocks traded on
The NASDAQ Stock Market, LLC(R), closing sale price shall mean the Nasdaq(R)
Official Closing Price as determined by The NASDAQ Stock Market, LLC(R). If
the Common Stocks are not so listed or, if so listed and the principal market
therefore is other than on the Primary Exchange or any appropriate secondary
exchange, the value shall generally be based on the current ask price on the
over-the-counter market (unless the Sponsor deems such price inappropriate as
a basis for evaluation). If current ask prices are unavailable, the value is
generally determined (a) on the basis of current ask prices for comparable
securities, (b) by appraising the value of the Common Stocks on the ask side
of the market, or (c) any combination of the above. If such prices are in a
currency other than U.S. dollars, the value of such Common Stock shall be
converted to U.S. dollars based on current exchange rates (unless the Sponsor

Page 19

deems such prices inappropriate as a basis for evaluation). The valuation of
LEAPS(R) written by the Trust will be determined as set forth above for Common
Stocks, with the exception that bid prices will be used instead of ask prices
during the initial offering period. If the Sponsor deems a price determined as
set forth above to be inappropriate as the basis for evaluation, the Sponsor
shall use such other information available to the Sponsor which it deems
appropriate as the basis for determining the value of a Security or LEAP(R).

After the initial offering period is over, the aggregate underlying value of
the Securities and LEAPS(R) will be determined as set forth above, except that
bid prices are used instead of ask prices when necessary for purposes of
valuing the Common Stocks and Treasury Obligations and ask prices are used
instead of bid prices when necessary for purposes of valuing the LEAPS(R).

The value of the Common Stocks and the value of the LEAPS(R) have an
interrelated effect on the value of a Unit. The value of the LEAPS(R) will be
affected by the value of the Common Stocks, the volatility of the Common
Stocks, the remaining time to the expiration of the LEAPS(R), the level of
interest rates and the dividend yields on the Common Stocks.

Distribution of Units

We intend to qualify Units of the Trust for sale in a number of states. All
Units will be sold at the then current Public Offering Price.

The Sponsor compensates intermediaries, such as broker/dealers and banks, for
their activities that are intended to result in sales of Units of the Trust.
This compensation includes dealer concessions described in the following
section and may include additional concessions and other compensation and
benefits to broker/dealers and other intermediaries.

Dealer Concessions.

Dealers and other selling agents can purchase Units at prices which reflect a
concession or agency commission of 1.25% of the Public Offering Price per
Unit, subject to reductions set forth in "Public Offering-Discounts for
Certain Persons."

Eligible dealer firms and other selling agents who, during the previous
consecutive 12-month period through the end of the most recent month, sold
primary market units of unit investment trusts sponsored by us in the dollar
amounts shown below will be entitled to up to the following additional sales
concession on primary market sales of units during the current month of unit
investment trusts sponsored by us:

Total sales Additional
(in millions) Concession
______________________________________________
$25 but less than $100 0.035%
$100 but less than $150 0.050%
$150 but less than $250 0.075%
$250 but less than $1,000 0.100%
$1,000 but less than $5,000 0.125%
$5,000 but less than $7,500 0.150%
$7,500 or more 0.175%

Dealers and other selling agents will not receive a concession on the sale of
Units which are not subject to a transactional sales charge, but such Units
will be included in determining whether the above volume sales levels are met.
Eligible dealer firms and other selling agents include clearing firms that
place orders with First Trust and provide First Trust with information with
respect to the representatives who initiated such transactions. Eligible
dealer firms and other selling agents will not include firms that solely
provide clearing services to other broker/dealer firms or firms who place
orders through clearing firms that are eligible dealers. We reserve the right
to change the amount of concessions or agency commissions from time to time.
Certain commercial banks may be making Units of the Trust available to their
customers on an agency basis. A portion of the transactional sales charge paid
by these customers is kept by or given to the banks in the amounts shown above.

Other Compensation and Benefits to Broker/Dealers.

The Sponsor, at its own expense and out of its own profits, currently provides
additional compensation and benefits to broker/dealers who sell Units of this
Trust and other First Trust products. This compensation is intended to result
in additional sales of First Trust products and/or compensate broker/dealers
and financial advisors for past sales. A number of factors are considered in
determining whether to pay these additional amounts. Such factors may include,
but are not limited to, the level or type of services provided by the
intermediary, the level or expected level of sales of First Trust products by
the intermediary or its agents, the placing of First Trust products on a
preferred or recommended product list, access to an intermediary's personnel,
and other factors. The Sponsor makes these payments for marketing, promotional
or related expenses, including, but not limited to, expenses of entertaining
retail customers and financial advisors, advertising, sponsorship of events or

Page 20

seminars, obtaining information about the breakdown of unit sales among an
intermediary's representatives or offices, obtaining shelf space in
broker/dealer firms and similar activities designed to promote the sale of the
Sponsor's products. The Sponsor makes such payments to a substantial majority
of intermediaries that sell First Trust products. The Sponsor may also make
certain payments to, or on behalf of, intermediaries to defray a portion of
their costs incurred for the purpose of facilitating Unit sales, such as the
costs of developing or purchasing trading systems to process Unit trades.
Payments of such additional compensation described in this and the preceding
paragraph, some of which may be characterized as "revenue sharing," create a
conflict of interest by influencing financial intermediaries and their agents
to sell or recommend a First Trust product, including the Trust, over products
offered by other sponsors or fund companies. These arrangements will not
change the price you pay for your Units.

Advertising and Investment Comparisons.

Advertising materials regarding the Trust may discuss several topics,
including: developing a long-term financial plan; working with your financial
professional; the nature and risks of various investment strategies and unit
investment trusts that could help you reach your financial goals; the
importance of discipline; how the Trust operates; how securities are selected;
various unit investment trust features such as convenience and costs; and
options available for certain types of unit investment trusts. These materials
may include descriptions of the principal businesses of the companies
represented in the Trust, research analysis of why they were selected and
information relating to the qualifications of the persons or entities
providing the research analysis. In addition, they may include research
opinions on the economy and industry sectors included and a list of investment
products generally appropriate for pursuing those recommendations.

From time to time we may compare the estimated returns of the Trust (which may
show performance net of the expenses and charges the Trust would have
incurred) and returns over specified periods of other similar trusts we
sponsor in our advertising and sales materials, with (1) returns on other
taxable investments such as the common stocks comprising various market
indexes, corporate or U.S. Government bonds, bank CDs and money market
accounts or funds, (2) performance data from Morningstar, Inc. or (3)
information from publications such as Money, The New York Times, U.S. News and
World Report, Bloomberg Businessweek, Forbes or Fortune. The investment
characteristics of the Trust differ from other comparative investments. You
should not assume that these performance comparisons will be representative of
the Trust's future performance. We may also, from time to time, use
advertising which classifies trusts or portfolio securities according to
capitalization and/or investment style.

The Sponsor's Profits

We will receive a gross sales commission equal to the maximum transactional
sales charge per Unit less any reduction as stated in "Public Offering." We
will also receive the amount of any collected creation and development fee.
Also, any difference between our cost to purchase the Securities and the price
at which we sell them to the Trust is considered a profit or loss (see Note 3
of "Notes to Schedule of Investments"). During the initial offering period,
dealers and others may also realize profits or sustain losses as a result of
fluctuations in the Public Offering Price they receive when they sell the Units.

In maintaining a market for the Units, any difference between the price at
which we purchase Units and the price at which we sell or redeem them will be
a profit or loss to us.

The Secondary Market

Although not obligated, we may maintain a market for the Units after the
initial offering period and continuously offer to purchase Units at prices
based on the Redemption Price per Unit.

We will pay all expenses to maintain a secondary market, except fees to value
Trust Securities and Trustee costs to transfer and record the ownership of
Units. We may discontinue purchases of Units at any time. IF YOU WISH TO
DISPOSE OF YOUR UNITS, YOU SHOULD ASK US FOR THE CURRENT MARKET PRICES BEFORE
MAKING A TENDER FOR REDEMPTION TO THE TRUSTEE. If you sell or redeem your
Units before you have paid the total deferred sales charge on your Units, you
will have to pay the remainder at that time.

How We Purchase Units

The Trustee will notify us of any tender of Units for redemption. If our bid
at that time is equal to or greater than the Redemption Price per Unit, we may
purchase the Units. You will receive your proceeds from the sale no later than
if they were redeemed by the Trustee. We may tender Units that we hold to the
Trustee for redemption as any other Units. If we elect not to purchase Units,

Page 21

the Trustee may sell tendered Units in the over-the-counter market, if any.
However, the amount you will receive is the same as you would have received on
redemption of the Units.

Expenses and Charges

The estimated annual expenses of the Trust are listed under "Fee Table." If
actual expenses of the Trust exceed the estimate, the Trust will bear the
excess. The Trustee will pay operating expenses of the Trust from the Income
Account of the Trust if funds are available, and then from the Capital
Account. The Income and Capital Accounts are non-interest-bearing to Unit
holders, so the Trustee may earn interest on these funds, thus benefiting from
their use.

First Trust Advisors L.P., an affiliate of ours, acts as Portfolio Supervisor
and will be compensated for providing portfolio supervisory services as well
as bookkeeping and other administrative services to the Trust. In providing
portfolio supervisory services, the Portfolio Supervisor may purchase research
services from a number of sources, which may include underwriters or dealers
of the Trust. As Sponsor, we will be compensated for providing evaluation
services and we will receive brokerage fees when the Trust uses us (or an
affiliate of ours) as agent in buying or selling Securities. As authorized by
the Indenture, the Trustee may employ a subsidiary or affiliate of the Trustee
to act as broker to execute certain transactions for the Trust. The Trust will
pay for such services at standard commission rates.

The fees payable to the Sponsor, First Trust Advisors L.P. and the Trustee are
based on the largest aggregate number of Units of the Trust outstanding at any
time during the calendar year, except during the initial offering period, in
which case these fees are calculated based on the largest number of Units
outstanding during the period for which compensation is paid. These fees may
be adjusted for inflation without Unit holders' approval, but in no case will
the annual fees paid to us or our affiliates for providing services to all
unit investment trusts be more than the actual cost of providing such services
in such year.

As Sponsor, we will receive a fee from the Trust for creating and developing
the Trust, including determining the Trust's objectives, policies, composition
and size, selecting service providers and information services and for
providing other similar administrative and ministerial functions. The
"creation and development fee" is a charge of $.050 per Unit outstanding at
the end of the initial offering period. The Trustee will deduct this amount
from the Trust's assets as of the close of the initial offering period. We do
not use this fee to pay distribution expenses or as compensation for sales
efforts. This fee will not be deducted from your proceeds if you sell or
redeem your Units before the end of the initial offering period.

In addition to the Trust's operating expenses and those fees described above,
the Trust may also incur the following charges:

- All legal expenses of the Trustee according to its responsibilities under
the Indenture;

- The expenses and costs incurred by the Trustee to protect the Trust and your
rights and interests (i.e., participating in litigation concerning a portfolio
security) and the costs of indemnifying the Trustee;

- Fees for any extraordinary services the Trustee performed under the Indenture;

- Payment for any loss, liability or expense the Trustee incurred without
negligence, bad faith or willful misconduct on its part, in connection with
its acceptance or administration of the Trust;

- Payment for any loss, liability or expenses we incurred without negligence,
bad faith or willful misconduct in acting as Sponsor of the Trust;

- Foreign custodial and transaction fees (which may include compensation paid
to the Trustee or its subsidiaries or affiliates), if any; and/or

- All taxes and other government charges imposed upon the Securities or any
part of the Trust.

The above expenses and the Trustee's annual fee are secured by a lien on the
Trust. In addition, if there is not enough cash in the Income or Capital
Account, the Trustee has the power to sell Securities to make cash available
to pay these charges which may result in capital gains or losses to you. See
"Tax Status."

Tax Status

Federal Tax Matters.

This section discusses some of the main U.S. federal income tax consequences
of owning Units of the Trust as of the date of this prospectus. Tax laws and
interpretations change frequently, and this summary does not describe all of
the tax consequences to all taxpayers. For example, this summary generally
does not describe your situation if you are a broker/dealer or other investor
with special circumstances. In addition, this section may not describe your
state, local or non-U.S. tax consequences.

Page 22

This federal income tax summary is based in part on the advice of counsel to
the Sponsor. The Internal Revenue Service ("IRS") could disagree with any
conclusions set forth in this section. In addition, our counsel may not have
been asked to review, and may not have reached a conclusion with respect to
the federal income tax treatment of the assets to be deposited in the Trust.
This summary may not be sufficient for you to use for the purpose of avoiding
penalties under federal tax law.

As with any investment, you should seek advice based on your individual
circumstances from your own tax advisor.

Trust Status.

Unit investment trusts maintain both Income and Capital Accounts, regardless
of tax structure. Please refer to the "Income and Capital Distributions"
section of the prospectus for more information.

The Trust intends to qualify as a "regulated investment company," commonly
known as a "RIC," under the federal tax laws. If the Trust qualifies as a RIC
and distributes its income as required by the tax law, the Trust generally
will not pay federal income taxes. For federal income tax purposes, you are
treated as the owner of the Trust Units and not of the assets held by the Trust.

Income from the Trust.

Trust distributions are generally taxable. After the end of each year, you
will receive a tax statement that separates the Trust's distributions into
ordinary income dividends, capital gain dividends and return of capital.
Income reported is generally net of expenses (but see "Treatment of Trust
Expenses" below). Ordinary income dividends are generally taxed at your
ordinary income tax rate, however, certain dividends received from the Trust
may be taxed at the capital gains tax rates. Generally, all capital gain
dividends are treated as long-term capital gains regardless of how long you
have owned your Units. In addition, the Trust may make distributions that
represent a return of capital for tax purposes and will generally not be
currently taxable to you, although they generally reduce your tax basis in
your Units and thus increase your taxable gain or decrease your loss when you
dispose of your Units. The tax laws may require you to treat distributions
made to you in January as if you had received them on December 31 of the
previous year.

Some distributions from the Trust may qualify as long-term capital gains,
which, if you are an individual, is generally taxed at a lower rate than your
ordinary income and short-term capital gain income. The distributions from the
Trust that you must take into account for federal income tax purposes are not
reduced by the amount used to pay a deferred sales charge, if any.
Distributions from the Trust, including capital gains, may also be subject to
a "Medicare tax" if your adjusted gross income exceeds certain threshold
amounts.

Certain Stock Dividends.

Ordinary income dividends received by an individual Unit holder from a RIC
such as the Trust are generally taxed at the same rates that apply to long-
term capital gains, provided certain holding period requirements are satisfied
and provided the dividends are attributable to qualifying dividend income
("QDI") received by the Trust itself. Dividends that do not meet these
requirements will generally be taxed at ordinary income tax rates. After the
end of the tax year, the Trust will provide a tax statement to its Unit
holders reporting the amount of any distribution which may be taken into
account as a dividend which is eligible for the capital gains tax rates.

Unit holders that are corporations may be eligible for the dividends received
deduction with respect to certain ordinary income dividends on Units that are
attributable to qualifying dividends received by the Trust from certain
corporations.

As part of its investment strategy the Trust has invested in certain
offsetting positions. Such offsetting positions may reduce the amount of
dividends that are eligible for the capital gains tax rates.

Sale of Units.

If you sell your Units (whether to a third party or to the Trust), you will
generally recognize a taxable gain or loss. To determine the amount of this
gain or loss, you must subtract your (adjusted) tax basis in your Units from
the amount you receive from the sale. Your original tax basis in your Units is
generally equal to the cost of your Units, including sales charges. In some
cases, however, you may have to adjust your tax basis after you purchase your
Units, in which case your gain would be calculated using your adjusted basis.

The tax statement you receive in regard to the sale or redemption of your
Units may contain information about your basis in the Units and whether any
gain or loss recognized by you should be considered long-term or short-term
capital gain. The information reported to you is based upon rules that do not
take into consideration all of the facts that may be known to you or to your
advisors. You should consult with your tax advisor about any adjustments that
may need to be made to the information reported to you in determining the
amount of your gain or loss.

Page 23

Treatment of Trust Expenses.

Expenses incurred and deducted by the Trust will generally not be treated as
income taxable to you. In some cases, however, you may be required to treat
your portion of these Trust expenses as income. You may not be able to take a
deduction for some or all of these expenses even if the cash you receive is
reduced by such expenses.

Investments in Certain Non-U.S. Corporations.

A foreign corporation will generally be treated as a passive foreign
investment company ("PFIC") if 75% or more of its income is passive income or
if 50% or more of its assets are held to produce passive income. If the Trust
holds an equity interest in PFICs, the Trust could be subject to U.S. federal
income tax and additional interest charges on gains and certain distributions
from the PFICs, even if all the income or gain is distributed in a timely
fashion to the Trust Unit holders. The Trust will not be able to pass through
to its Unit holders any credit or deduction for such taxes if the taxes are
imposed at the Trust level. The Trust may be able to make an election that
could limit the tax imposed on the Trust. In this case, the Trust would
recognize as ordinary income any increase in the value of such PFIC shares,
and as ordinary loss any decrease in such value to the extent it did not
exceed prior increases included in income.

Under this election, the Trust might be required to recognize income in excess
of its distributions from the PFICs and its proceeds from dispositions of PFIC
stock during that year, and such income would nevertheless be subject to the
distribution requirement and would be taken into account for purposes of
determining the application of the 4% excise tax imposed on RICs that do not
meet certain distribution thresholds. Dividends paid by PFICs are not treated
as QDI to shareholders of the PFICs.

Non-U.S. Investors.

If you are a non-U.S. investor, distributions from the Trust treated as
dividends will generally be subject to a U.S. withholding tax of 30% of the
distribution. Certain dividends, such as capital gains dividends, short-term
capital gains dividends, and distributions that are attributable to certain
interest income, may not be subject to U.S. withholding taxes. In addition,
some non-U.S. investors may be eligible for a reduction or elimination of U.S.
withholding taxes under a treaty. However, the qualification for those
exclusions may not be known at the time of the distribution.

Separately, the United States, pursuant to the Foreign Account Tax Compliance
Act ("FATCA") imposes a 30% tax on certain non-U.S. entities that receive U.S.
source interest or dividends if the non-U.S. entity does not comply with
certain U.S. disclosure and reporting requirements. This FATCA tax also
currently applies to the gross proceeds from the disposition of securities
that produce U.S. source interest or dividends. However, proposed regulations
may eliminate the requirement to withhold on payments of gross proceeds from
dispositions.

It is the responsibility of the entity through which you hold your Units to
determine the applicable withholding.

Foreign Tax Credit.

If the Trust directly or indirectly invests in non-U.S. stocks, the tax
statement that you receive may include an item showing foreign taxes the Trust
paid to other countries. You may be able to deduct or receive a tax credit for
your share of these taxes. The Trust would have to meet certain IRS
requirements in order to pass through credits to you.

You should consult your tax advisor regarding potential foreign, state or
local taxation with respect to your Units.

Retirement Plans

You may purchase Units of the Trust for:

- Individual Retirement Accounts;

- Keogh Plans;

- Pension funds; and

- Other tax-deferred retirement plans.

Generally, the federal income tax on capital gains and income received in each
of the above plans is deferred until you receive distributions. These
distributions are generally treated as ordinary income but may, in some cases,
be eligible for special averaging or tax-deferred rollover treatment. Before
participating in a plan like this, you should review the tax laws regarding
these plans and consult your attorney or tax advisor. Brokerage firms and
other financial institutions offer these plans with varying fees and charges.

Rights of Unit Holders

Unit Ownership.

Ownership of Units will not be evidenced by certificates. If you purchase or
hold Units through a broker/dealer or bank, your ownership of Units will be
recorded in book-entry form at the Depository Trust Company ("DTC") and

Page 24

credited on its records to your broker/dealer's or bank's DTC account.
Transfer of Units will be accomplished by book entries made by DTC and its
participants if the Units are registered to DTC or its nominee, Cede & Co. DTC
will forward all notices and credit all payments received in respect of the
Units held by the DTC participants. You will receive written confirmation of
your purchases and sales of Units from the broker/dealer or bank through which
you made the transaction. You may transfer your Units by contacting the
broker/dealer or bank through which you hold your Units.

Unit Holder Reports.

The Trustee will prepare a statement detailing the per Unit amounts (if any)
distributed from the Income Account and Capital Account in connection with
each distribution. In addition, at the end of each calendar year, the Trustee
will prepare a statement which contains the following information:

- A summary of transactions in the Trust for the year;

- A list of any Securities sold during the year and the Securities held at the
end of that year by the Trust;

- The Redemption Price per Unit, computed on the 31st day of December of such
year (or the last business day before); and

- Amounts of income and capital distributed during the year.

By February 15th yearly, the Annual Reports are posted to the Sponsor's website
(www.ftportfolios.com) in the UIT Tax Center and retrievable by CUSIP. You may
also request one be sent to you by calling the Sponsor at 800-621-1675, dept.
code 2. In addition, you may also request from the Trustee copies of the
evaluations of the Securities as prepared by the Sponsor to enable you to comply
with applicable federal and state tax reporting requirements.

Income and Capital Distributions

You will begin receiving distributions on your Units only after you become a
Record Owner. The Trustee will credit dividends and interest received on the
Trust's Securities to the Income Account of the Trust. All other receipts,
such as return of capital or capital gain dividends, are credited to the
Capital Account of the Trust. Dividends received on foreign Securities, if
any, are converted into U.S. dollars at the applicable exchange rate.

The Trustee will distribute money from the Income Account, as determined at
the semi-annual Record Date, semi-annually on the twenty-fifth day of each
June and December to Unit holders of record on the tenth day of such months
provided the amount equals at least $1.00 per 100 Units. No income
distribution will be paid if accrued expenses of the Trust exceed amounts in
the Income Account on the Distribution Dates. Distribution amounts will vary
with changes in the Trust's fees and expenses, in dividends received and with
the sale of Securities. If the Capital Account contains proceeds from any
matured Securities as of the tenth day of a month, the Trustee will distribute
money in the Capital Account on the twenty-fifth day of such month to Unit
holders of record on the tenth day of such month. In other months, the Trustee
will only distribute money in the Capital Account if the amount available for
distribution from that account equals at least $1.00 per 100 Units. In any
case, the Trustee may distribute funds in the Capital Account in December of
each year to avoid imposition of any income or excise taxes on undistributed
income in the Trust and will distribute funds as part of the final liquidation
distribution.

If an Income or Capital Account distribution date is a day on which the NYSE
is closed, the distribution will be made on the next day the stock exchange is
open. Distributions are paid to Unit holders of record determined as of the
close of business on the Record Date for that distribution or, if the Record
Date is a day on which the NYSE is closed, the first preceding day on which
the exchange is open.

We anticipate that there will be enough money in the Capital Account of the
Trust to pay the deferred sales charge to the Sponsor. If not, the Trustee may
sell Securities to meet the shortfall.

Within a reasonable time after the Trust is terminated, you will receive the
pro rata share of the money from the sale of the Securities and amounts in the
Income and Capital Accounts. All Unit holders will receive a pro rata share of
any other assets remaining in the Trust, after deducting any unpaid expenses.

The Trustee may establish reserves (the "Reserve Account") within the Trust to
cover anticipated state and local taxes or any governmental charges to be paid
out of the Trust.

Redeeming Your Units

You may redeem all or a portion of your Units at any time by sending a request
for redemption to your broker/dealer or bank through which you hold your
Units. No redemption fee will be charged, but you are responsible for any
governmental charges that apply. Certain broker/dealers may charge a

Page 25

transaction fee for processing redemption requests. Two business days after
the day you tender your Units (the "Date of Tender") you will receive cash in
an amount for each Unit equal to the Redemption Price per Unit calculated at
the Evaluation Time on the Date of Tender.

The Date of Tender is considered to be the date on which your redemption
request is received by the Trustee from the broker/dealer or bank through
which you hold your Units (if such day is a day the NYSE is open for trading).
However, if the redemption request is received after 4:00 p.m. Eastern time
(or after any earlier closing time on a day on which the NYSE is scheduled in
advance to close at such earlier time), the Date of Tender is the next day the
NYSE is open for trading.

Any amounts paid on redemption representing income will be withdrawn from the
Income Account if funds are available for that purpose, or from the Capital
Account. All other amounts paid on redemption will be taken from the Capital
Account.

The Trustee may sell Securities to make funds available for redemption. The
Trustee will purchase the LEAPS(R) which will cancel it and then sell the
underlying Common Stocks. Because of the minimum amounts in which the LEAPS(R)
must be traded, the proceeds of Common Stocks sold subject to the LEAPS(R) may
exceed the amount required at the time to redeem Units. These excess proceeds
will be distributed to Unit holders. If Securities are sold, the size and
diversification of the Trust will be reduced. These sales may result in lower
prices than if the Securities were sold at a different time.

Your right to redeem Units (and therefore, your right to receive payment) may
be delayed:

- If the NYSE is closed (other than customary weekend and holiday closings);

- If the SEC determines that trading on the NYSE is restricted or that an
emergency exists making sale or evaluation of the Securities not reasonably
practical; or

- For any other period permitted by SEC order.

The Trustee is not liable to any person for any loss or damage which may
result from such a suspension or postponement.

The Redemption Price.

The Redemption Price per Unit is determined by the Trustee by:

adding

1. cash in the Income and Capital Accounts of the Trust not designated to
purchase Securities;

2. the aggregate underlying value of the Securities held in the Trust;

3. dividends receivable on the Securities trading ex-dividend as of the date
of computation; and

4. accrued interest on the Treasury Obligations; and

deducting

1. the aggregate value of the LEAPS(R);

2. any applicable taxes or governmental charges that need to be paid out of
the Trust;

3. any amounts owed to the Trustee for its advances;

4. estimated accrued expenses of the Trust, if any;

5. cash held for distribution to Unit holders of record of the Trust as of the
business day before the evaluation being made;

6. liquidation costs for foreign Securities, if any; and

7. other liabilities incurred by the Trust; and

dividing

1. the result by the number of outstanding Units of the Trust.

Any remaining deferred sales charge on the Units when you redeem them will be
deducted from your redemption proceeds. In addition, until they are collected,
the Redemption Price per Unit will include estimated organization costs as set
forth under "Fee Table."

Removing Securities from the Trust

The portfolio of the Trust is not managed. However, we may, but are not
required to, direct the Trustee to dispose of a Security (and its related
LEAPS(R)) in certain limited circumstances, including situations in which:

- The issuer of the Security defaults in the payment of principal, interest or
a declared dividend;

- Any action or proceeding prevents the payment of principal, interest or
dividends;

- There is any legal question or impediment affecting the Security;

- The issuer of the Security has breached a covenant which would affect the
payment of principal, interest or dividends, the issuer's credit standing, or
otherwise damage the sound investment character of the Security;

- The issuer has defaulted on the payment of any other of its outstanding
obligations;

- There has been a public tender offer made for a Security or a merger or
acquisition is announced affecting a Security, and that in our opinion the

Page 26

sale or tender of the Security is in the best interest of Unit holders;

- Such factors arise which, in our opinion, adversely affect the tax or
exchange control status of the Securities;

- The sale of Securities is necessary or advisable (i) in order to maintain
the qualification of the Trust as a "regulated investment company" in the case
of the Trust which has elected to qualify as such or (ii) to provide funds to
make any distribution for a taxable year in order to avoid imposition of any
income or excise taxes on undistributed income in the Trust which is a
"regulated investment company";

- The price of the Security has declined to such an extent, or such other
credit factors exist, that in our opinion keeping the Security would be
harmful to the Trust;

- As a result of the ownership of the Security, the Trust or its Unit holders
would be a direct or indirect shareholder of a passive foreign investment
company;

- Such factors arise which, in our opinion, adversely affect the tax or
exchange control status of the Securities; or

- The sale of the Security is necessary for the Trust to comply with such
federal and/or state laws, regulations and/or regulatory actions and
interpretations which may be in effect from time to time.

If a Security defaults in the payment of principal or interest and no
provision for payment is made, the Trustee must notify us of this fact. If we
fail to instruct the Trustee whether to sell or hold the Security within 30
days of our being notified, the Trustee may, in its discretion, sell any
defaulted Securities and will not be liable for any depreciation or loss
incurred thereby.

Except for instances in which the Trust acquires Replacement Securities, as
described in "The FT Series," the Trust will generally not acquire any
securities or other property other than the Securities. The Trustee, on behalf
of the Trust and at the direction of the Sponsor, will vote for or against any
offer for new or exchanged securities or property in exchange for a Security,
such as those acquired in a merger or other transaction. If such exchanged
securities or property are acquired by the Trust, at our instruction, they
will either be sold or held in the Trust. In that regard, we may instruct the
Trustee to accept such an offer or to take any other action with respect
thereto as we may deem proper if the issuer is in default with respect to such
Securities or in our written opinion the issuer will likely default in respect
to such Securities in the foreseeable future. Any obligations received in
exchange or substitution will be held by the Trustee subject to the terms and
conditions in the Indenture to the same extent as Securities originally
deposited in the Trust. In making the determination as to whether to sell or
hold the exchanged securities or property we may get advice from the Portfolio
Supervisor. Any proceeds received from the sale of Securities, exchanged
securities or property will be credited to the Capital Account of the Trust
for distribution to Unit holders or to meet redemption requests. The Trustee
may retain and pay us or an affiliate of ours to act as agent for the Trust to
facilitate selling Securities, exchanged securities or property from the
Trust. If we or our affiliate act in this capacity, we will be held subject to
the restrictions under the 1940 Act. When acting in an agency capacity, we may
select various broker/dealers to execute securities transactions on behalf of
the Trust, which may include broker/dealers who sell Units of the Trust. We do
not consider sales of Units of the Trust or any other products sponsored by
First Trust as a factor in selecting such broker/dealers. As authorized by the
Indenture, the Trustee may also employ a subsidiary or affiliate of the
Trustee to act as broker in selling such Securities or property. The Trust
will pay for these brokerage services at standard commission rates.

The Trustee may sell Securities designated by us, or, absent our direction, at
its own discretion, in order to meet redemption requests or pay expenses. In
designating Securities to be sold, we will try to maintain the proportionate
relationship among the Securities. If this is not possible, the composition
and diversification of the Trust may be changed.

Amending or Terminating the Indenture

Amendments. The Indenture may be amended by us and the Trustee without your
consent:

- To cure ambiguities;

- To correct or supplement any defective or inconsistent provision;

- To make any amendment required by any governmental agency; or

- To make other changes determined not to be adverse to your best interests
(as determined by us and the Trustee).

Termination. As provided by the Indenture, the Trust will terminate on the
Mandatory Termination Date as stated in the "Summary of Essential
Information." The Trust may be terminated earlier:

Page 27

- Upon the consent of 100% of the Unit holders of the Trust;

- If the value of the Securities owned by the Trust as shown by any evaluation
is less than the lower of $2,000,000 or 20% of the total value of Securities
deposited in the Trust during the initial offering period ("Discretionary
Liquidation Amount"); or

- In the event that Units of the Trust not yet sold aggregating more than 60%
of the Units of the Trust are tendered for redemption by underwriters,
including the Sponsor.

If the Trust is terminated due to this last reason, we will refund your entire
sales charge; however, termination of the Trust before the Mandatory
Termination Date for any other stated reason will result in all remaining
unpaid deferred sales charges on your Units being deducted from your
termination proceeds. For various reasons, the Trust may be reduced below the
Discretionary Liquidation Amount and could therefore be terminated before the
Mandatory Termination Date.

Unless terminated earlier, the Trustee will begin to sell Securities in
connection with the termination of the Trust during the period beginning nine
business days prior to, and no later than, the Mandatory Termination Date. We
will determine the manner and timing of the sale of Securities. Because the
Trustee must sell the Securities within a relatively short period of time, the
sale of Securities as part of the termination process may result in a lower
sales price than might otherwise be realized if such sale were not required at
this time.

The scheduled Mandatory Termination Date will be subsequent to the expiration
date of the LEAPS(R). If the LEAPS(R) are exercised prior to their expiration,
the Trust will receive cash; if the LEAPS(R) are not exercised, the Trust will
continue to hold the Common Stocks in the Portfolio. If the Trust is
terminated early, the Trustee will either (a) sell the Common Stocks subject
to the LEAPS(R); or (b) enter into a closing purchase transaction as a result
of which the LEAPS(R) will be canceled and then sell the underlying Common
Stocks.

You will receive a cash distribution from the sale of the remaining
Securities, along with your interest in the Income and Capital Accounts,
within a reasonable time after the Trust is terminated. The Trustee will
deduct from the Trust any accrued costs, expenses, advances or indemnities
provided for by the Indenture, including estimated compensation of the Trustee
and costs of liquidation and any amounts required as a reserve to pay any
taxes or other governmental charges.

Information on the Sponsor and Trustee

The Sponsor.

We, First Trust Portfolios L.P., specialize in the underwriting, trading and
wholesale distribution of unit investment trusts under the "First Trust" brand
name and other securities. An Illinois limited partnership formed in 1991, we
took over the First Trust product line and act as Sponsor for successive
series of:

- The First Trust Combined Series

- FT Series (formerly known as The First Trust Special Situations Trust)

- The First Trust Insured Corporate Trust

- The First Trust of Insured Municipal Bonds

- The First Trust GNMA

The First Trust product line commenced with the first insured unit investment
trust in 1974. To date we have deposited more than $545 billion in First Trust
unit investment trusts. Our employees include a team of professionals with
many years of experience in the unit investment trust industry.

We are a member of FINRA and SIPC. Our principal offices are at 120 East
Liberty Drive, Wheaton, Illinois 60187; telephone number 800-621-1675. As of
December 31, 2021, the total partners' capital of First Trust Portfolios L.P.
was $125,276,503.

This information refers only to us and not to the Trust or to any series of
the Trust or to any other dealer. We are including this information only to
inform you of our financial responsibility and our ability to carry out our
contractual obligations. We will provide more detailed financial information
on request.

Code of Ethics. The Sponsor and the Trust have adopted a code of ethics
requiring the Sponsor's employees who have access to information on Trust
transactions to report personal securities transactions. The purpose of the
code is to avoid potential conflicts of interest and to prevent fraud,
deception or misconduct with respect to the Trust.

The Trustee.

The Trustee is The Bank of New York Mellon, a trust company organized under
the laws of New York. The Bank of New York Mellon has its unit investment
trust division offices at 240 Greenwich Street, New York, New York 10286,
telephone 800-813-3074. If you have questions regarding your account or your
Trust, please contact the Trustee at its unit investment trust division
offices or your financial advisor. The Sponsor does not have access to

Page 28

individual account information. The Bank of New York Mellon is subject to
supervision and examination by the Superintendent of the New York State
Department of Financial Services and the Board of Governors of the Federal
Reserve System, and its deposits are insured by the Federal Deposit Insurance
Corporation to the extent permitted by law.

The Trustee has not participated in selecting the Securities; it only provides
administrative services.

Limitations of Liabilities of Sponsor and Trustee.

Neither we nor the Trustee will be liable for taking any action or for not
taking any action in good faith according to the Indenture. We will also not
be accountable for errors in judgment. We will only be liable for our own
willful misfeasance, bad faith, gross negligence (ordinary negligence in the
Trustee's case) or reckless disregard of our obligations and duties. The
Trustee is not liable for any loss or depreciation when the Securities are
sold. If we fail to act under the Indenture, the Trustee may do so, and the
Trustee will not be liable for any action it takes in good faith under the
Indenture.

The Trustee will not be liable for any taxes or other governmental charges or
interest on the Securities which the Trustee may be required to pay under any
present or future law of the United States or of any other taxing authority
with jurisdiction. Also, the Indenture states other provisions regarding the
liability of the Trustee.

If we do not perform any of our duties under the Indenture or are not able to
act or become bankrupt, or if our affairs are taken over by public
authorities, then the Trustee may:

- Appoint a successor sponsor, paying them a reasonable rate not more than
that stated by the SEC;

- Terminate the Indenture and liquidate the Trust; or

- Continue to act as Trustee without terminating the Indenture.

The Trustee and Unit holders may rely on the accuracy of any evaluation
prepared by the Sponsor. The Sponsor will make determinations in good faith
based upon the best available information, but will not be liable to the
Trustee or Unit holders for errors in judgment.

Other Information

Legal Opinions.

Our counsel is Chapman and Cutler LLP, 320 S. Canal St., Chicago, Illinois
60606. They have passed upon the legality of the Units offered hereby and
certain matters relating to federal tax law. Carter Ledyard & Milburn LLP acts
as the Trustee's counsel.

Experts.

The Trust's statement of net assets, including the schedule of investments, as
of the opening of business on the Initial Date of Deposit included in this
prospectus, has been audited by Deloitte & Touche LLP, an independent
registered public accounting firm, as stated in their report appearing herein,
and is included in reliance upon the report of such firm given upon their
authority as experts in accounting and auditing.

Supplemental Information.

If you write or call the Sponsor, you will receive free of charge supplemental
information about this Series, which has been filed with the SEC and to which
we have referred throughout. This information states more specific details
concerning the nature, structure and risks of this product.

Page 29

This page is intentionally left blank.

Page 30

This page is intentionally left blank.

Page 31

FIRST TRUST(R)

Defensive Equity Buy-Write Portfolio Series
FT 10412

Sponsor:

First Trust Portfolios L.P.

Member SIPC o Member FINRA
120 East Liberty Drive
Wheaton, Illinois 60187
800-621-1675

Trustee:

The Bank of New York Mellon

240 Greenwich Street
New York, New York 10286
800-813-3074
24-Hour Pricing Line:
800-446-0132
Please refer to the "Summary of Essential Information" for the Product Code.

________________________

When Units of the Trust are no longer available, this prospectus may be used
as a preliminary prospectus
for a future series, in which case you should note the following:

THE INFORMATION IN THE PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. WE MAY
NOT SELL, OR ACCEPT OFFERS TO BUY, SECURITIES OF A FUTURE SERIES UNTIL THAT
SERIES HAS BECOME EFFECTIVE WITH THE SEC. NO SECURITIES CAN BE SOLD IN ANY
STATE WHERE A SALE WOULD BE ILLEGAL.

________________________

This prospectus contains information relating to the above-mentioned unit
investment trust, but does not contain all of the information about this
investment company as filed with the SEC in Washington, D.C. under the:

- Securities Act of 1933 (file no. 333-267939) and

- Investment Company Act of 1940 (file no. 811-05903)

Information about the Trust, including its Code of Ethics, can be reviewed and
copied at the SEC's Public Reference Room in Washington, D.C. Information
regarding the operation of the SEC's Public Reference Room may be obtained by
calling the SEC at 202-942-8090.

Information about the Trust is available on the EDGAR Database on the SEC's
Internet site at www.sec.gov.

To obtain copies at prescribed rates -

Write: Public Reference Section of the SEC
100 F Street, N.E.
Washington, D.C. 20549
e-mail address: publicinfo@sec.gov

December 1, 2022

PLEASE RETAIN THIS PROSPECTUS FOR FUTURE REFERENCE

Page 32

FIRST TRUST(R)

The FT Series

Information Supplement

This Information Supplement provides additional information concerning the
structure, operations and risks of the unit investment trust contained in FT
10412 not found in the prospectus for the Trust. This Information Supplement
is not a prospectus and does not include all of the information you should
consider before investing in the Trust. This Information Supplement should be
read in conjunction with the prospectus for the Trust in which you are
considering investing.

This Information Supplement is dated December 1, 2022. Capitalized terms have
been defined in the prospectus.

Table of Contents

Risk Factors
Securities 1
Dividends 1
Foreign Issuers 1
Small and/or Mid Capitalization Companies 2
Utilities 2
Concentrations
Concentration Risk 3
Consumer Staples 3
Health Care 4
Common Stocks Selected for Defensive Equity Buy-Write Portfolio Series 4

Risk Factors

Securities. An investment in Units should be made with an understanding of the
risks which an investment in common stocks entails, including the risk that
the financial condition of the issuers of the Securities or the general
condition of the relevant stock market may worsen, and the value of the
Securities and therefore the value of the Units may decline. Common stocks are
especially susceptible to general stock market movements and to volatile
increases and decreases of value, as market confidence in and perceptions of
the issuers change. These perceptions are based on unpredictable factors,
including expectations regarding government, economic, monetary and fiscal
policies, inflation and interest rates, economic expansion or contraction, and
global or regional political, economic or banking crises.

Dividends. Shareholders of common stocks have rights to receive payments from
the issuers of those common stocks that are generally subordinate to those of
creditors of, or holders of debt obligations or preferred stocks of, such
issuers. Shareholders of common stocks have a right to receive dividends only
when and if, and in the amounts, declared by the issuer's board of directors
and have a right to participate in amounts available for distribution by the
issuer only after all other claims on the issuer have been paid or provided
for. Common stocks do not represent an obligation of the issuer and,
therefore, do not offer any assurance of income or provide the same degree of
protection of capital as do debt securities. The issuance of additional debt
securities or preferred stock will create prior claims for payment of
principal, interest and dividends which could adversely affect the ability and
inclination of the issuer to declare or pay dividends on its common stock or
the rights of holders of common stock with respect to assets of the issuer
upon liquidation or bankruptcy. Cumulative preferred stock dividends must be
paid before common stock dividends, and any cumulative preferred stock
dividend omitted is added to future dividends payable to the holders of
cumulative preferred stock. Preferred stockholders are also generally entitled
to rights on liquidation which are senior to those of common stockholders.

Foreign Issuers. The following section applies to individual Trusts which
contain Securities issued by, or invest in securities issued by, foreign
entities. Since certain of the Securities held by the Trust consist of, or
invest in, securities issued by foreign entities, an investment in the Trust
involves certain investment risks that are different in some respects from an
investment in a trust which invests solely in the securities of domestic
entities. These investment risks include future political or governmental
restrictions which might adversely affect the payment or receipt of payment of

Page 1

dividends on the relevant Securities, the possibility that the financial
condition of the issuers of the Securities may become impaired or that the
general condition of the relevant stock market may worsen (both of which would
contribute directly to a decrease in the value of the Securities and thus in
the value of the Units), the limited liquidity and relatively small market
capitalization of the relevant securities market, expropriation or
confiscatory taxation, economic uncertainties and foreign currency
devaluations and fluctuations. In addition, for foreign issuers that are not
subject to the reporting requirements of the Securities Exchange Act of 1934,
as amended, there may be less publicly available information than is available
from a domestic issuer. Also, foreign issuers are not necessarily subject to
uniform accounting, auditing and financial reporting standards, practices and
requirements comparable to those applicable to domestic issuers. The
securities of many foreign issuers are less liquid and their prices more
volatile than securities of comparable domestic issuers. In addition, fixed
brokerage commissions and other transaction costs on foreign securities
exchanges are generally higher than in the United States and there is
generally less government supervision and regulation of exchanges, brokers and
issuers in foreign countries than there is in the United States. However, due
to the nature of the issuers of the Securities selected for the Trust, the
Sponsor believes that adequate information will be available to allow the
Supervisor to provide portfolio surveillance for the Trust.

Securities issued by non-U.S. issuers may pay interest and/or dividends in
foreign currencies and may be principally traded in foreign currencies.
Therefore, there is a risk that the U.S. dollar value of these interest and/or
dividend payments and/or securities will vary with fluctuations in foreign
exchange rates.

On the basis of the best information available to the Sponsor at the present
time, none of the Securities in the Trust are subject to exchange control
restrictions under existing law which would materially interfere with payment
to the Trust of dividends due on, or proceeds from the sale of, the
Securities. However, there can be no assurance that exchange control
regulations might not be adopted in the future which might adversely affect
payment to the Trust. The adoption of exchange control regulations and other
legal restrictions could have an adverse impact on the marketability of
international securities in the Trust and on the ability of the Trust to
satisfy its obligation to redeem Units tendered to the Trustee for redemption.
In addition, restrictions on the settlement of transactions on either the
purchase or sale side, or both, could cause delays or increase the costs
associated with the purchase and sale of the foreign Securities and
correspondingly could affect the price of the Units.

Investors should be aware that it may not be possible to buy all Securities at
the same time because of the unavailability of any Security, and restrictions
applicable to the Trust relating to the purchase of a Security by reason of
the federal securities laws or otherwise.

Foreign securities generally have not been registered under the Securities Act
of 1933 and may not be exempt from the registration requirements of such Act.
Sales of non-exempt Securities by the Trust in the United States securities
markets are subject to severe restrictions and may not be practicable.
Accordingly, sales of these Securities by the Trust will generally be effected
only in foreign securities markets. Although the Sponsor does not believe that
the Trust will encounter obstacles in disposing of the Securities, investors
should realize that the Securities may be traded in foreign countries where
the securities markets are not as developed or efficient and may not be as
liquid as those in the United States. The value of the Securities will be
adversely affected if trading markets for the Securities are limited or absent.

Small and/or Mid Capitalization Companies. The following section applies to
individual Trusts which contain Securities issued by, or invest in Securities
that hold securities issued by, small and/or mid capitalization companies.
While historically stocks of small and mid capitalization companies have
outperformed the stocks of large companies, the former have customarily
involved more investment risk as well. Such companies may have limited product
lines, markets or financial resources; may lack management depth or
experience; and may be more vulnerable to adverse general market or economic
developments than large companies. Some of these companies may distribute,
sell or produce products which have recently been brought to market and may be
dependent on key personnel.

The prices of small and mid cap company securities are often more volatile
than prices associated with large company issues, and can display abrupt or
erratic movements at times, due to limited trading volumes and less publicly
available information. Also, because such companies normally have fewer shares
outstanding and these shares trade less frequently than large companies, it
may be more difficult for the Trusts which contain these Securities to buy and
sell significant amounts of such shares without an unfavorable impact on
prevailing market prices.

Utilities. General problems of the public utility sector include risks of
increases in fuel and other operating costs; restrictions on operations and
increased costs and delays as a result of environmental, nuclear safety and
other regulations; regulatory restrictions on the ability to pass increasing
wholesale costs along to the retail and business customer; energy

Page 2

conservation; technological innovations which may render existing plants,
equipment or products obsolete; the effects of local weather, maturing markets
and difficulty in expanding to new markets due to regulatory and other
factors; natural or man-made disasters; difficulty obtaining adequate returns
on invested capital; the high cost of obtaining financing during periods of
inflation; difficulties of the capital markets in absorbing utility debt and
equity securities; and increased competition. There is no assurance that such
public service commissions will, in the future, grant rate increases or that
any such increases will be adequate to cover operating and other expenses and
debt service requirements. All of the public utilities which are issuers of
the Securities in the portfolio have been experiencing many of these problems
in varying degrees. Furthermore, utility stocks are particularly susceptible
to interest rate risk, generally exhibiting an inverse relationship to
interest rates. As a result, utility stock prices may be adversely affected as
interest rates rise. The Sponsor makes no prediction as to whether interest
rates will rise or fall or the effect, if any, interest rates may have on the
Securities in the portfolio. In addition, federal, state and municipal
governmental authorities may from time to time review existing, and impose
additional, regulations governing the licensing, construction and operation of
nuclear power plants, which may adversely affect the ability of the issuers of
certain of the Securities in the Trust's portfolio to make dividend payments
on their Securities.

Utilities are generally subject to extensive regulation by state utility
commissions which, for example, establish the rates which may be charged and
the appropriate rate of return on an approved asset base, which must be
approved by the state commissions. The value of utility company securities may
decline as a result of changes to governmental regulation controlling the
utilities industry. Adverse regulatory changes could prevent or delay
utilities from passing along cost increases to customers, which could hinder a
utility's ability to meet its obligations to its suppliers.

Additionally, certain utilities have had difficulty from time to time in
persuading regulators, who are subject to political pressures, to grant rate
increases necessary to maintain an adequate return on investment and voters in
many states have the ability to impose limits on rate adjustments (for
example, by initiative or referendum). Any unexpected limitations could
negatively affect the profitability of utilities whose budgets are planned far
in advance. In addition, gas pipeline and distribution companies have had
difficulties in adjusting to short and surplus energy supplies, enforcing or
being required to comply with long-term contracts and avoiding litigation from
their customers, on the one hand, or suppliers, on the other.

Mergers in the utility sector may require approval from several federal and
state regulatory agencies. These regulatory authorities could, as a matter of
policy, reverse the trend toward deregulation and make consolidation more
difficult, or cause delay in the merger process, any of which could cause the
prices of these securities to fall. Certain of the issuers of the Securities
in the Trust may own or operate nuclear generating facilities. Governmental
authorities may from time to time review existing, and impose additional,
requirements governing the licensing, construction and operation of nuclear
power plants. Nuclear generating projects in the electric utility industry
have experienced substantial cost increases, construction delays and licensing
difficulties. These have been caused by various factors, including inflation,
high financing costs, required design changes and rework, allegedly faulty
construction, objections by groups and governmental officials, limits on the
ability to finance, reduced forecasts of energy requirements and economic
conditions. This experience indicates that the risk of significant cost
increases, delays and licensing difficulties remain present until completion
and achievement of commercial operation of any nuclear project. Also, nuclear
generating units in service have experienced unplanned outages or extensions
of scheduled outages due to equipment problems or new regulatory requirements
sometimes followed by a significant delay in obtaining regulatory approval to
return to service. A major accident at a nuclear plant anywhere, such as the
accident at a plant in Chernobyl, could cause the imposition of limits or
prohibitions on the operation, construction or licensing of nuclear units in
the United States.

Concentrations

The Trust is concentrated in stocks of companies within each of the consumer
staples and health care sectors.

Page 3

litigation resulting from accidents, extensive competition (including that of
low-cost foreign competition), unfunded pension fund liabilities and employee
and retiree benefit costs and financial deterioration resulting from leveraged
buy-outs, takeovers or acquisitions. Historically, the demand for consumer
staples goods has remained fairly constant regardless of the state of the
economy. With some products, such as food, alcohol and tobacco, demand
sometimes increases during economic downturns. However, price competition
among suppliers may be very challenging, which can drive prices lower and
impact returns. Other factors of particular relevance to the profitability of
the sector are the effects of increasing environmental regulation on packaging
and on waste disposal, the continuing need to conform with foreign regulations
governing packaging and the environment, the outcome of trade negotiations and
the effect on foreign subsidies and tariffs, foreign exchange rates, the price
of oil and its effect on energy costs, inventory cutbacks by retailers,
transportation and distribution costs, health concerns relating to the
consumption of certain products, the effect of demographics on consumer
demand, the availability and cost of raw materials and the ongoing need to
develop new products and to improve productivity.

Health Care. Health care companies include those involved in health
care/managed care, hospital management/health services, the creation and
development of drugs and biotechnology, and the development of advanced
medical devices, instruments and other supplies, all of which have unique
potential risks. These companies are subject to governmental regulation of
their products and services, a factor which could have a significant and
unfavorable effect on the price and availability of such products or services.
Furthermore, such companies face the risk of increasing competition from new
products or services, generic drug sales, the termination of patent protection
for drug or medical supply products and the risk that technological advances
will render their products obsolete. The research and development costs of
bringing a drug to market are substantial, and include lengthy governmental
review processes with no guarantee that the product will ever come to market.
Many of these companies may have operating losses and may not offer certain
products for several years. Such companies may also have persistent losses
during a new product's transition from development to production, and revenue
patterns may be erratic. On a worldwide basis, such companies are involved in
the development and distributions of drugs, vaccines, medical products and
medical services.

As the number of older people in the United States increases, the health care
system is increasingly burdened by the costs related to chronic illnesses,
injuries, disabilities, nursing home care and home health care. These costs
may be exaggerated for health care facility operators who may already be
burdened by events and conditions including fluctuating demand for services,
the ability of the facility to provide the services required, physicians'
confidence in the facility, management capabilities, competition with other
hospitals, efforts by insurers and governmental agencies to limit rates,
legislation establishing state rate-setting agencies, expenses, government
regulation, the cost and possible unavailability of malpractice insurance and
the termination or restriction of governmental financial assistance, including
that associated with Medicare, Medicaid and other similar third party
programs. The challenges presented by an increase in the elderly population
may require an increase in spending to improve and expand the health care
infrastructure as well as overall reform to the entire health care system.

Legislative proposals concerning health care are proposed in Congress from
time to time. These proposals span a wide range of topics, including cost and
price controls (which may include a freeze on the prices of prescription
drugs), national health insurance, incentives for competition in the provision
of health care services, tax incentives and penalties related to health care
insurance premiums and promotion of pre-paid health care plans. The long-term
effects of any such proposals on the health care sector remain uncertain and
cannot be predicted.

Common Stocks Selected for Defensive Equity Buy-Write Portfolio Series

Consumer Staples
________________

Archer-Daniels-Midland Company, headquartered in Chicago, Illinois, is engaged
in the business of procuring, transporting, storing, processing, and
merchandising agricultural commodities and products, including oil seeds, corn
and wheat.

British American Tobacco Plc (ADR), headquartered in London, England, through
its subsidiaries, provides tobacco and nicotine products including cigarettes
and roll-your-own tobacco, as well as cigars, cigarillos, pipe tobacco, snus,
electronic cigarettes and nicotine inhalation. The company has an active
business presence in approximately 180 countries around the world.

The Coca-Cola Company, headquartered in Atlanta, Georgia, makes and
distributes soft drink concentrates and syrups and also markets juice and
juice-drink products. The company's products are sold in more than 200
countries and include the leading soft drink products in most of these
countries.

Page 4

Constellation Brands, Inc. (Class A), headquartered in Victor, New York,
produces and markets branded beverage alcohol products, including beer, wines
and distilled spirits. The company's product names include "Robert Mondavi,"
"Manischewitz," "Simi," "Arbor Mist," "Svedka Vodka" and "Corona."

Costco Wholesale Corporation, headquartered in Issaquah, Washington, operates
a chain of wholesale cash-and-carry membership warehouses that sell high-
quality, nationally branded and select private label merchandise at low prices
to businesses and individuals who are members of selected employee groups. The
company's warehouses are located internationally.

Mondelez International, Inc., headquartered in Chicago, Illinois,
manufactures, markets and sells food products worldwide. The company's
products include beverages, cookies, crackers, snacks, chocolate, gum and candy.

The Procter & Gamble Company, headquartered in Cincinnati, Ohio, manufactures
and markets consumer products worldwide. The company's products are available
in the laundry and cleaning, paper, beauty care, food and beverage, and health
care segments.

Walmart, Inc., headquartered in Bentonville, Arkansas, is an international
consumer staples company. The company owns and operates retail department
stores, supercenters, full-line supermarkets and warehouse clubs.

Health Care
___________

AbbVie Inc., headquartered in North Chicago, Illinois, is a research-based
pharmaceuticals company. The company discovers, develops and commercializes
advanced therapies in immunology, oncology, women's health, neuroscience and
other areas.

Cigna Corporation, headquartered in Bloomfield, Connecticut, is an insurance
company. The company offers life, accident, dental and health insurance along
with other products and services to individuals, families and businesses.

CVS Health Corporation, headquartered in Woonsocket, Rhode Island, is a
drugstore chain specializing in prescription drugs, over-the-counter drugs,
photofinishing services and film, greeting cards, beauty and cosmetics,
convenience foods and seasonal merchandise.

Danaher Corporation, headquartered in Washington, D.C., produces and sells
electronic test tools in its Life Sciences and Diagnostics segment and offers
consumables, equipment and services to diagnose, treat and prevent disease
ailments of the teeth, gums and supporting bone in its Dental segment. The
company operates worldwide.

Elevance Health Inc., headquartered in Indianapolis, Indiana, through its
subsidiaries, operates as a commercial health benefits company in the United
States. The company offers a spectrum of network-based managed care plans to
the large and small employer, individual, Medicaid and senior markets.

Eli Lilly and Company, headquartered in Indianapolis, Indiana, with
subsidiaries, develops, makes and markets pharmaceutical and animal health
products sold in countries around the world. The company also provides health
care management services in the United States.

McKesson Corporation, headquartered in Irving, Texas, is a health care
services company providing distribution and technology solutions to the health
care industry. The company delivers pharmaceuticals, medical-surgical supplies
and health care products to pharmacies and institutional providers. The
company also provides software and services designed to improve connectivity
and communications and to help reduce costs.

Novo Nordisk A/S (ADR), headquartered in Bagsvaerd, Denmark, is a health care
company that specializes in products for the treatment of diabetes, as well as
products in the areas of coagulation disorders, human growth hormones and
hormone replacement.

Pfizer Inc., headquartered in New York, New York, is a research-based
pharmaceutical company. The company develops, manufactures and sells
medicines, vaccines, medical devices and consumer health care products
worldwide.

Regeneron Pharmaceuticals, Inc., headquartered in Tarrytown, New York, is a
biopharmaceutical company. The company discovers, develops and commercializes
medicines for the treatment of serious medical conditions in the United States.

Thermo Fisher Scientific Inc., headquartered in Waltham, Massachusetts,
provides technology-based instruments, systems and components that offer
solutions for markets ranging from life sciences to telecommunications to
food, drug and beverage production.

Page 5

Vertex Pharmaceuticals Incorporated, headquartered in Boston, Massachusetts,
discovers, develops and markets small molecule drugs that address the
treatment of viral diseases, cancer, autoimmune and inflammatory diseases and
neurological disorders.

Utilities
_________

American Electric Power Company, Inc., headquartered in Columbus, Ohio, is a
public utility holding company engaged in the generation, transmission and
distribution of electric power. The company's service area covers portions of
Arkansas, Indiana, Kentucky, Louisiana, Michigan, Ohio, Oklahoma, Tennessee,
Texas, Virginia and West Virginia.

Exelon Corporation, headquartered in Chicago, Illinois, is an electric utility
holding company. Together with its subsidiaries, the company owns, contracts
and invests in electric generating facilities such as nuclear, hydroelectric
generation, wind and solar facilities.

NextEra Energy, Inc., headquartered in Juno Beach, Florida, through its
subsidiaries, engages in the generation, transmission, distribution and sale
of electric energy in the United States and Canada.

NRG Energy, Inc., headquartered in Houston, Texas, operates as a wholesale
power generation company. The company sells and delivers energy and energy
products and services primarily in the United States.

Sempra Energy, headquartered in San Diego, California, is an energy services
company whose primary subsidiaries are San Diego Gas & Electric Company and
Southern California Gas Company. The company, together with its subsidiaries,
provides electric and gas service to San Diego and southern Orange County.

We have obtained the foregoing company descriptions from third-party sources
we deem reliable.

Page 6

Undertakings

Subject to the terms and conditions of Section 15(d) of the Securities Exchange Act of 1934, the undersigned registrant hereby undertakes to file with the Securities and Exchange Commission such supplementary and periodic information, documents, and reports as may be prescribed by any rule or regulation of the Commission heretofore or hereafter duly adopted pursuant to authority conferred in that section.

Insofar as indemnification for liability arising under the Securities Act of 1933 (the “Securities Act”) may be permitted to directors, officers and controlling persons of the registrant pursuant to Rule 484 under the Securities Act, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

CONTENTS OF REGISTRATION STATEMENT

Bonding Arrangements of Depositor:

First Trust Portfolios L.P. is covered by a Brokers' Fidelity Bond, in the total amount of $2,000,000, the insurer being National Union Fire Insurance Company of Pittsburgh.

This Registration Statement on Form S-6 comprises the following papers and documents:

The facing sheet

The Prospectus

The signatures

Exhibits

S-1

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant, FT 10412, has duly caused this Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wheaton and State of Illinois on December 1, 2022.

FT 10412

By:

First Trust Portfolios L.P.
Depositor

By:

/s/ Elizabeth H. Bull
Senior Vice President

S-2

Pursuant to the requirements of the Securities Act of 1933, this Amendment to the Registration Statement has been signed below by the following person in the capacity and on the date indicated:

Name	Title*	Date

James A. Bowen	Director of The Charger Corporation, the General Partner of First Trust Portfolios L.P., and Chief Executive Officer of First Trust Portfolios L.P.	) ) ) )By: /s/ Elizabeth H. Bull ) Attorney-in-Fact** ) December 1, 2022
James M. Dykas	Chief Financial Officer of First Trust Portfolios L.P.	) )
Christina Knierim	Controller of First Trust Portfolios L.P.	) )

The title of the person named herein represents his or her capacity in and relationship to First Trust Portfolios L.P., the Depositor.

Executed copies of the related powers of attorney were filed with the Securities and Exchange Commission in connection with the Amendment No. 1 to Form S-6 of FT 10131 (File No. 333-264568) and the same is hereby incorporated herein by this reference.

S-3

CONSENT OF COUNSEL

The consent of counsel to the use of its name in the Prospectus included in this Registration Statement is contained in its opinion filed as Exhibit 3.1 of the Registration Statement.

Consent of Independent Registered Public Accounting Firm

The consent of Deloitte & Touche LLP to the use of its name in the Prospectus included in the Registration Statement is filed as Exhibit 4.1 to the Registration Statement.

S-4

EXHIBIT INDEX

1.1

Standard Terms and Conditions of Trust for FT 10292 and certain subsequent Series, effective September 7, 2022 among First Trust Portfolios L.P., as Depositor, The Bank of New York Mellon, as Trustee and First Trust Advisors L.P., as Portfolio Supervisor (incorporated by reference to Amendment No. 1 to Form S-6 [File No. 333-266325] filed on behalf of FT 10292).

1.1.1

Trust Agreement for FT 10412, effective December 1, 2022 among First Trust Portfolios L.P., as Depositor, The Bank of New York Mellon, as Trustee, and First Trust Advisors L.P., as Portfolio Supervisor.

1.2

Certificate of Limited Partnership of Nike Securities, L.P., predecessor of First Trust Portfolios L.P. (incorporated by reference to Amendment No. 1 to Form S-6 [File No. 333-230481] filed on behalf of FT 8001).

1.3

Amended and Restated Limited Partnership Agreement of Nike Securities, L.P., predecessor of First Trust Portfolios L.P. (incorporated by reference to Amendment No. 1 to Form S-6 [File No. 333-230481] filed on behalf of FT 8001).

1.4

Articles of Incorporation of Nike Securities Corporation, predecessor to The Charger Corporation, the general partner of First Trust Portfolios L.P., Depositor (incorporated by reference to Amendment No. 1 to Form S-6 [File No. 333-230481] filed on behalf of FT 8001).

1.5

By-Laws of The Charger Corporation, the general partner of First Trust Portfolios L.P., Depositor (incorporated by reference to Amendment No. 2 to Form S-6 [File No. 333-169625] filed on behalf of FT 2669).

1.7

Fund of Funds Agreements (incorporated by reference to Amendment No. 1 to Form S-6 [File No. 333-261661] filed on behalf of FT 9909, Amendment No. 1 to Form S-6 [File No. 333-261297] filed on behalf of FT 9857, Amendment No. 1 to Form S-6 [File No. 333-262164] filed on behalf of FT 9948, Amendment No. 1 to Form S-6 [File No. 333-262344] filed on behalf of FT 9965 and Amendment No. 1 to Form S-6 [File No. 333-263845] filed on behalf of FT 10083).

2.2

Code of Ethics (incorporated by reference to Amendment No. 1 to Form S-6 [File No. 333-224320] filed on behalf of FT 7359).

S-5

3.1

Opinion of counsel as to legality of securities being registered.

4.1

Consent of Independent Registered Public Accounting Firm.

6.1

List of Principal Officers of the Depositor (incorporated by reference to Amendment No. 1 to Form S-6 [File No. 333-236093] filed on behalf of FT 8556).

7.1

Powers of Attorney executed by the Officers listed on page S-3 of this Registration Statement (incorporated by reference to Amendment No. 1 to Form S-6 [File No. 333-264568] filed on behalf of FT 10131).

S-6